<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML+RDFa 1.0//EN"
  "http://www.w3.org/MarkUp/DTD/xhtml-rdfa-1.dtd">

  <!--[if lt IE 7]> <html class="no-mqs lt-ie9 lt-ie8 lt-ie7" lang="en" xml:lang="en" dir="ltr" > <![endif]-->
  <!--[if IE 7]>    <html class="no-mqs lt-ie9 lt-ie8" lang="en" xml:lang="en" dir="ltr" > <![endif]-->
  <!--[if IE 8]>    <html class="no-mqs lt-ie9" lang="en" xml:lang="en" dir="ltr" > <![endif]-->
  <!--[if gt IE 8]><!--> <html xml:lang="en" lang="en" dir="ltr" > <!--<![endif]-->
  <!--[if IE 9]>    <html class="no-mqs" lang="en" xml:lang="en" dir="ltr" > <![endif]-->
<!-- <html lang="" dir=""> -->
<head profile="http://www.w3.org/1999/xhtml/vocab">
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel=”apple-touch-icon-precomposed” href=”/sites/default/themes/bmj/the_bmj/img/icon.png”/>
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <!--[if IE]><![endif]-->
<link rel="dns-prefetch" href="//static.polldaddy.com" />
<link rel="dns-prefetch" href="//ajax.googleapis.com" />
<link rel="dns-prefetch" href="//crossmark-cdn.crossref.org" />
<link rel="dns-prefetch" href="//d1bxh8uas1mnw7.cloudfront.net" />
<link rel="dns-prefetch" href="//www.google.com" />
<link rel="dns-prefetch" href="//scholar.google.com" />
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<link rel="shortcut icon" href="https://www.bmj.com/sites/default/themes/bmj/the_bmj/favicon.ico" type="image/vnd.microsoft.icon" />
<!--[if (gte IE 6)&(lte IE 9)]><script src="/sites/default/themes/bmj/the_bmj/js/respond.min.js" />
</script><![endif]--><link href="//netdna.bootstrapcdn.com/font-awesome/4.0.3/css/font-awesome.css" rel="stylesheet" media="all" type="text/css" />
<link rel="alternate" type="application/pdf" title="Full Text (PDF)" href="/content/369/bmj.m1849.full.pdf" />
<link rel="alternate" type="application/vnd.ms-powerpoint" title="Powerpoint" href="/content/369/bmj.m1849.ppt" />
<link rel="alternate" type="application/xml" title="XML" href="/content/369/bmj.m1849.download.xml" />
<link rel="alternate" type="text/plain" title="Full Text (Plain)" href="/content/369/bmj.m1849.full.txt" />
<meta name="type" content="article" />
<meta name="category" content="research-article" />
<meta name="HW.identifier" content="/bmj/369/bmj.m1849.atom" />
<meta name="HW.pisa" content="bmj;369/may14_5/m1849" />
<meta name="DC.Format" content="text/html" />
<meta name="DC.Language" content="en" />
<meta name="DC.Title" content="Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial" />
<meta name="DC.Identifier" content="10.1136/bmj.m1849" />
<meta name="DC.Date" content="2020-05-14" />
<meta name="DC.Publisher" content="British Medical Journal Publishing Group" />
<meta name="DC.Rights" content="© Author(s) (or their employer(s)) 2019. Re-use permitted under CC
                BY. No commercial re-use. See rights and permissions. Published by
                BMJ.. http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/." />
<meta name="DC.AccessRights" content="open-access" />
<meta name="DC.Relation" content="10.1136/bmj.m1091" />
<meta name="DC.Relation" content="10.1136/bmj.m1443" />
<meta name="DC.Relation" content="10.1136/bmj.m2018" />
<meta name="DC.Relation" content="10.1136/bmj.m2980" />
<meta name="DC.Description" content="Objective To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).

Design Multicentre, open label, randomised controlled trial.

Setting 16 government designated covid-19 treatment centres in China, 11 to 29 February 2020.

Participants 150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone).

Interventions Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively).

Main outcome measure Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according to the intention to treat principle. Adverse events were analysed in the safety population in which hydroxychloroquine recipients were participants who received at least one dose of hydroxychloroquine and hydroxychloroquine non-recipients were those managed with standard of care alone.

Results Of 150 patients, 148 had mild to moderate disease and two had severe disease. The mean duration from symptom onset to randomisation was 16.6 (SD 10.5; range 3-41) days. A total of 109 (73%) patients (56 standard of care; 53 standard of care plus hydroxychloroquine) had negative conversion well before 28 days, and the remaining 41 (27%) patients (19 standard of care; 22 standard of care plus hydroxychloroquine) were censored as they did not reach negative conversion of virus. The probability of negative conversion by 28 days in the standard of care plus hydroxychloroquine group was 85.4% (95% confidence interval 73.8% to 93.8%), similar to that in the standard of care group (81.3%, 71.2% to 89.6%). The difference between groups was 4.1% (95% confidence interval –10.3% to 18.5%). In the safety population, adverse events were recorded in 7/80 (9%) hydroxychloroquine non-recipients and in 21/70 (30%) hydroxychloroquine recipients. The most common adverse event in the hydroxychloroquine recipients was diarrhoea, reported in 7/70 (10%) patients. Two hydroxychloroquine recipients reported serious adverse events.

Conclusions Administration of hydroxychloroquine did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate covid-19. Adverse events were higher in hydroxychloroquine recipients than in non-recipients.

Trial registration ChiCTR2000029868." />
<meta name="DC.Contributor" content="Wei Tang" />
<meta name="DC.Contributor" content="Zhujun Cao" />
<meta name="DC.Contributor" content="Mingfeng Han" />
<meta name="DC.Contributor" content="Zhengyan Wang" />
<meta name="DC.Contributor" content="Junwen Chen" />
<meta name="DC.Contributor" content="Wenjin Sun" />
<meta name="DC.Contributor" content="Yaojie Wu" />
<meta name="DC.Contributor" content="Wei Xiao" />
<meta name="DC.Contributor" content="Shengyong Liu" />
<meta name="DC.Contributor" content="Erzhen Chen" />
<meta name="DC.Contributor" content="Wei Chen" />
<meta name="DC.Contributor" content="Xiongbiao Wang" />
<meta name="DC.Contributor" content="Jiuyong Yang" />
<meta name="DC.Contributor" content="Jun Lin" />
<meta name="DC.Contributor" content="Qingxia Zhao" />
<meta name="DC.Contributor" content="Youqin Yan" />
<meta name="DC.Contributor" content="Zhibin Xie" />
<meta name="DC.Contributor" content="Dan Li" />
<meta name="DC.Contributor" content="Yaofeng Yang" />
<meta name="DC.Contributor" content="Leshan Liu" />
<meta name="DC.Contributor" content="Jieming Qu" />
<meta name="DC.Contributor" content="Guang Ning" />
<meta name="DC.Contributor" content="Guochao Shi" />
<meta name="DC.Contributor" content="Qing Xie" />
<meta name="article:published_time" content="2020-05-14" />
<meta name="article:section" content="Research" />
<meta name="citation_title" content="Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial" />
<meta name="citation_abstract" lang="en" content="&lt;h3&gt;Abstract&lt;/h3&gt;
&lt;h3&gt;Objective&lt;/h3&gt;
&lt;p&gt;To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).&lt;/p&gt;&lt;h3&gt;Design&lt;/h3&gt;
&lt;p&gt;Multicentre, open label, randomised controlled trial.&lt;/p&gt;&lt;h3&gt;Setting&lt;/h3&gt;
&lt;p&gt;16 government designated covid-19 treatment centres in China, 11 to 29 February 2020.&lt;/p&gt;&lt;h3&gt;Participants&lt;/h3&gt;
&lt;p&gt;150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone).&lt;/p&gt;&lt;h3&gt;Interventions&lt;/h3&gt;
&lt;p&gt;Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively).&lt;/p&gt;&lt;h3&gt;Main outcome measure&lt;/h3&gt;
&lt;p&gt;Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according to the intention to treat principle. Adverse events were analysed in the safety population in which hydroxychloroquine recipients were participants who received at least one dose of hydroxychloroquine and hydroxychloroquine non-recipients were those managed with standard of care alone.&lt;/p&gt;&lt;h3&gt;Results&lt;/h3&gt;
&lt;p&gt;Of 150 patients, 148 had mild to moderate disease and two had severe disease. The mean duration from symptom onset to randomisation was 16.6 (SD 10.5; range 3-41) days. A total of 109 (73%) patients (56 standard of care; 53 standard of care plus hydroxychloroquine) had negative conversion well before 28 days, and the remaining 41 (27%) patients (19 standard of care; 22 standard of care plus hydroxychloroquine) were censored as they did not reach negative conversion of virus. The probability of negative conversion by 28 days in the standard of care plus hydroxychloroquine group was 85.4% (95% confidence interval 73.8% to 93.8%), similar to that in the standard of care group (81.3%, 71.2% to 89.6%). The difference between groups was 4.1% (95% confidence interval –10.3% to 18.5%). In the safety population, adverse events were recorded in 7/80 (9%) hydroxychloroquine non-recipients and in 21/70 (30%) hydroxychloroquine recipients. The most common adverse event in the hydroxychloroquine recipients was diarrhoea, reported in 7/70 (10%) patients. Two hydroxychloroquine recipients reported serious adverse events.&lt;/p&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;
&lt;p&gt;Administration of hydroxychloroquine did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate covid-19. Adverse events were higher in hydroxychloroquine recipients than in non-recipients.&lt;/p&gt;&lt;h3&gt;Trial registration&lt;/h3&gt;
&lt;p&gt;ChiCTR2000029868.&lt;/p&gt;" />
<meta name="citation_journal_title" content="BMJ" />
<meta name="citation_publisher" content="British Medical Journal Publishing Group" />
<meta name="citation_publication_date" content="2020/05/14" />
<meta name="citation_mjid" content="bmj;369/may14_5/m1849" />
<meta name="citation_id" content="369/may14_5/m1849" />
<meta name="citation_public_url" content="https://www.bmj.com/content/369/bmj.m1849" />
<meta name="citation_abstract_html_url" content="https://www.bmj.com/content/369/bmj.m1849.abstract" />
<meta name="citation_full_html_url" content="https://www.bmj.com/content/369/bmj.m1849.full" />
<meta name="citation_pdf_url" content="https://www.bmj.com/content/bmj/369/bmj.m1849.full.pdf" />
<meta name="citation_issn" content="1756-1833" />
<meta name="citation_journal_abbrev" content="BMJ" />
<meta name="citation_doi" content="10.1136/bmj.m1849" />
<meta name="citation_pmid" content="32409561" />
<meta name="citation_volume" content="369" />
<meta name="citation_article_type" content="Research Article" />
<meta name="citation_section" content="Research" />
<meta name="citation_access" content="all" />
<meta name="citation_author" content="Wei Tang" />
<meta name="citation_author_institution" content="Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China" />
<meta name="citation_author_institution" content="Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China" />
<meta name="citation_author" content="Zhujun Cao" />
<meta name="citation_author_institution" content="Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China" />
<meta name="citation_author" content="Mingfeng Han" />
<meta name="citation_author_institution" content="Department of Respiratory Medicine, No 2 People’s Hospital of Fuyang City, Fuyang, Anhui, China" />
<meta name="citation_author" content="Zhengyan Wang" />
<meta name="citation_author_institution" content="Department of Respiratory Medicine, Suizhou Hospital, Hubei University of Medicine, Suizhou, Hubei, China" />
<meta name="citation_author" content="Junwen Chen" />
<meta name="citation_author_institution" content="Department of Respiratory and Critical Care Medicine, Xiangyang No 1 People’s Hospital, Hubei University of Medicine, Xiangyang, Hubei, China" />
<meta name="citation_author" content="Wenjin Sun" />
<meta name="citation_author_institution" content="Department of Infectious Diseases, Central Hospital of Ezhou, Ezhou, Hubei, China" />
<meta name="citation_author" content="Yaojie Wu" />
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Yunmeng People’s Hospital, Xiaogan, Hubei, China" />
<meta name="citation_author" content="Wei Xiao" />
<meta name="citation_author_institution" content="Department of Respiratory Medicine, First People’s Hospital of Jingzhou City, Jingzhou, Hubei, China" />
<meta name="citation_author" content="Shengyong Liu" />
<meta name="citation_author_institution" content="Department of Infectious Diseases, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei, China" />
<meta name="citation_author" content="Erzhen Chen" />
<meta name="citation_author_institution" content="Department of Emergency Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China" />
<meta name="citation_author" content="Wei Chen" />
<meta name="citation_author_institution" content="Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China" />
<meta name="citation_author_institution" content="Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China" />
<meta name="citation_author" content="Xiongbiao Wang" />
<meta name="citation_author_institution" content="Department of Respiratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China" />
<meta name="citation_author" content="Jiuyong Yang" />
<meta name="citation_author_institution" content="Department of Respiratory Medicine, Hubei Space Hospital of Xiaogan, Xiaogan, Hubei, China" />
<meta name="citation_author" content="Jun Lin" />
<meta name="citation_author_institution" content="Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China" />
<meta name="citation_author" content="Qingxia Zhao" />
<meta name="citation_author_institution" content="Department of Infectious Disease, The Sixth People’s Hospital of Zhengzhou, Zhengzhou, Henan, China" />
<meta name="citation_author" content="Youqin Yan" />
<meta name="citation_author_institution" content="Department of Infectious Disease, Wuhan No 7 Hospital, Wuhan, Hubei, China" />
<meta name="citation_author" content="Zhibin Xie" />
<meta name="citation_author_institution" content="Departments of Respiratory Medicine, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei, China" />
<meta name="citation_author" content="Dan Li" />
<meta name="citation_author_institution" content="Department of Respiratory Medicine, The Third People’s Hospital of Yichang, Yichang, Hubei, China" />
<meta name="citation_author" content="Yaofeng Yang" />
<meta name="citation_author_institution" content="Department of Respiratory Medicine, Xiao Gan First People’s Hospital, Xiaogan, Hubei Province, China" />
<meta name="citation_author" content="Leshan Liu" />
<meta name="citation_author_institution" content="Clinical Research Centre, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China" />
<meta name="citation_author" content="Jieming Qu" />
<meta name="citation_author_institution" content="Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China" />
<meta name="citation_author_institution" content="Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China" />
<meta name="citation_author" content="Guang Ning" />
<meta name="citation_author_institution" content="Shanghai National Research Centre for Endocrine and Metabolic Diseases, State Key Laboratory of Medical Genomics, Shanghai Institute for Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China" />
<meta name="citation_author" content="Guochao Shi" />
<meta name="citation_author_institution" content="Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China" />
<meta name="citation_author_institution" content="Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China" />
<meta name="citation_author" content="Qing Xie" />
<meta name="citation_author_institution" content="Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China" />
<meta name="citation_author_orcid" content="http://orcid.org/0000-0002-2582-8803" />
<meta name="citation_reference" content="Coronavirus covid-19 global cases by Johns Hopkins CSSE. https://www.arcgis.com/apps/opsdashboard/index.html#/85320e2ea5424dfaaa75ae62e5c06e61." />
<meta name="citation_reference" content="citation_journal_title=Drugs;citation_author=J. Dyall;citation_author=R. Gross;citation_author=J. Kindrachuk;citation_title=Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies;citation_pages=1935-66;citation_volume=77;citation_year=2017;citation_pmid=http://www.n;citation_doi=10.1007/s40265-017-0830-1" />
<meta name="citation_reference" content="citation_journal_title=N Engl J Med;citation_author=B. Cao;citation_author=Y. Wang;citation_author=D. Wen;citation_title=A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19;citation_year=2020;citation_pmid=32187464;citation_doi=10.1056/NEJMoa2001282" />
<meta name="citation_reference" content="citation_journal_title=Cell Res;citation_author=M. Wang;citation_author=R. Cao;citation_author=L. Zhang;citation_title=Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro;citation_volume=30;citation_year=2020;citation_pmid=32020029;citation_doi=10.1038/s41422-020-0282-0" />
<meta name="citation_reference" content="citation_journal_title=Clin Infect Dis;citation_author=X. Yao;citation_author=F. Ye;citation_author=M. Zhang;citation_title=In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);citation_year=2020;citation_pmid=http://www.n;citation_doi=10.1093/cid/ciaa237" />
<meta name="citation_reference" content="citation_journal_title=Biosci Trends;citation_author=J. Gao;citation_author=Z. Tian;citation_author=X. Yang;citation_title=Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of covid-19 associated pneumonia in clinical studies;citation_volume=14;citation_year=2020;citation_pmid=32074550;citation_doi=10.5582/bst.2020.01047" />
<meta name="citation_reference" content="National Health Commission of the People’s Republic of China. Chinese guideline for the management COVID-19 (version 7.0, in Chinese). 2020. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf." />
<meta name="citation_reference" content="US Food and Drug Administration. Emergency Use Authorization. Hydroxychloroquine sulfate health care provider fact sheet. https://www.fda.gov/media/136534/download." />
<meta name="citation_reference" content="Piller C. “This is insane!” Many scientists lament Trump's embrace of risky malaria drugs for coronavirus. 2020. https://www.sciencemag.org/news/2020/03/insane-many-scientists-lament-trump-s-embrace-risky-malaria-drugs-coronavirus#." />
<meta name="citation_reference" content="citation_journal_title=Inflammopharmacology;citation_author=KD. Rainsford;citation_author=AL. Parke;citation_author=M. Clifford-Rashotte;citation_author=WF. Kean;citation_title=Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases;citation_pages=231-69;citation_volume=23;citation_year=2015;citation_pmid=26246395;citation_doi=10.1007/s10787-015-0239-y" />
<meta name="citation_reference" content="citation_journal_title=N Engl J Med;citation_author=LR. Baden;citation_author=EJ. Rubin;citation_title=Covid-19 - the search for effective therapy;citation_year=2020;citation_doi=10.1056/NEJMe2005477" />
<meta name="citation_reference" content="National Health Commission of the People’s Republic of China. Chinese guideline for the management covid-19 (version 5.0, in Chinese). 2020. http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab6bec7f93e64e7f998d802991203cd6.pdf." />
<meta name="citation_reference" content="citation_journal_title=BMJ;citation_author=T. Chen;citation_author=D. Wu;citation_author=H. Chen;citation_title=Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [correction in: BMJ 2020;368:m1295];citation_volume=368;citation_year=2020;citation_pmid=32217556;citation_doi=10.1136/bmj.m1091" />
<meta name="citation_reference" content="citation_journal_title=BMJ;citation_author=S. Zheng;citation_author=J. Fan;citation_author=F. Yu;citation_title=Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study;citation_volume=369;citation_year=2020;citation_pmid=32317267;citation_doi=10.1136/bmj.m1443" />
<meta name="citation_reference" content="citation_journal_title=Clin Infect Dis;citation_author=SA. Harper;citation_author=JS. Bradley;citation_author=JA. Englund;citation_title=Seasonal influenza in adults and children–diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America;citation_volume=48;citation_year=2009;citation_pmid=19281331;citation_doi=10.1086/598513" />
<meta name="citation_reference" content="citation_journal_title=Arthritis and rheumatism;citation_journal_abbrev=Arthritis Rheum;citation_author=T. Munster;citation_author=JP. Gibbs;citation_author=D. Shen;citation_title=Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.;citation_pages=1460-1469;citation_volume=46;citation_year=2002;citation_issue=6;citation_pmid=12115175;citation_doi=10.1002/art.10307" />
<meta name="citation_reference" content="citation_journal_title=Am J Ophthalmol;citation_author=LS. Leung;citation_author=JW. Neal;citation_author=HA. Wakelee;citation_author=LV. Sequist;citation_author=MF. Marmor;citation_title=Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy;citation_pages=799-805.e1;citation_volume=160;citation_year=2015;citation_pmid=26189086;citation_doi=10.1016/j.ajo.2015.07.012" />
<meta name="citation_reference" content="citation_journal_title=Clinical therapeutics;citation_journal_abbrev=Clin Ther;citation_author=EN. van Roon;citation_author=PM. van den Bemt;citation_author=TL. Jansen;citation_author=NM. Houtman;citation_author=MA. van de Laar;citation_author=JR. Brouwers;citation_title=An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.;citation_pages=1737-1746;citation_volume=31;citation_year=2009;citation_issue=8;citation_pmid=19808132;citation_doi=10.1016/j.clinthera.2009.08.009" />
<meta name="citation_reference" content="citation_journal_title=New England Journal of Medicine;citation_journal_abbrev=NEJM;citation_author=WA. Ray;citation_author=KT. Murray;citation_author=S. Meredith;citation_author=SS. Narasimhulu;citation_author=K. Hall;citation_author=CM. Stein;citation_title=Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes;citation_pages=1089-1096;citation_volume=351;citation_year=2004;citation_issue=11;citation_pmid=15356306;citation_doi=10.1056/NEJMoa040582" />
<meta name="citation_reference" content="citation_journal_title=Clinical Infectious Diseases;citation_journal_abbrev=Clinical Infectious Diseases;citation_author=RC. Owens;citation_author=TD. Nolin;citation_title=Antimicrobial-associated QT interval prolongation: pointes of interest.;citation_pages=1603-1611;citation_volume=43;citation_year=2006;citation_issue=12;citation_pmid=17109296;citation_doi=10.1086/508873" />
<meta name="citation_reference" content="citation_journal_title=Nat Rev Rheumatol;citation_author=E. Schrezenmeier;citation_author=T. Dörner;citation_title=Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology;citation_pages=155-66;citation_volume=16;citation_year=2020;citation_pmid=http://www.n;citation_doi=10.1038/s41584-020-0372-x" />
<meta name="citation_reference" content="citation_journal_title=JAMA;citation_author=W. Wang;citation_author=Y. Xu;citation_author=R. Gao;citation_title=Detection of SARS-CoV-2 in different types of clinical specimens;citation_year=2020;citation_pmid=32159775;citation_doi=10.1001/jama.2020.3786" />
<meta name="citation_fulltext_world_readable" content="" />
<meta name="twitter:title" content="Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:description" content="Objective To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).

Design Multicentre, open label, randomised controlled trial.

Setting 16 government designated covid-19 treatment centres in China, 11 to 29 February 2020.

Participants 150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone).

Interventions Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively).

Main outcome measure Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according to the intention to treat principle. Adverse events were analysed in the safety population in which hydroxychloroquine recipients were participants who received at least one dose of hydroxychloroquine and hydroxychloroquine non-recipients were those managed with standard of care alone.

Results Of 150 patients, 148 had mild to moderate disease and two had severe disease. The mean duration from symptom onset to randomisation was 16.6 (SD 10.5; range 3-41) days. A total of 109 (73%) patients (56 standard of care; 53 standard of care plus hydroxychloroquine) had negative conversion well before 28 days, and the remaining 41 (27%) patients (19 standard of care; 22 standard of care plus hydroxychloroquine) were censored as they did not reach negative conversion of virus. The probability of negative conversion by 28 days in the standard of care plus hydroxychloroquine group was 85.4% (95% confidence interval 73.8% to 93.8%), similar to that in the standard of care group (81.3%, 71.2% to 89.6%). The difference between groups was 4.1% (95% confidence interval –10.3% to 18.5%). In the safety population, adverse events were recorded in 7/80 (9%) hydroxychloroquine non-recipients and in 21/70 (30%) hydroxychloroquine recipients. The most common adverse event in the hydroxychloroquine recipients was diarrhoea, reported in 7/70 (10%) patients. Two hydroxychloroquine recipients reported serious adverse events.

Conclusions Administration of hydroxychloroquine did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate covid-19. Adverse events were higher in hydroxychloroquine recipients than in non-recipients.

Trial registration ChiCTR2000029868." />
<meta name="og-title" property="og:title" content="Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial" />
<meta name="og-url" property="og:url" content="https://www.bmj.com/content/369/bmj.m1849" />
<meta name="og-site-name" property="og:site_name" content="The BMJ" />
<meta name="og-description" property="og:description" content="Objective To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).

Design Multicentre, open label, randomised controlled trial.

Setting 16 government designated covid-19 treatment centres in China, 11 to 29 February 2020.

Participants 150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone).

Interventions Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively).

Main outcome measure Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according to the intention to treat principle. Adverse events were analysed in the safety population in which hydroxychloroquine recipients were participants who received at least one dose of hydroxychloroquine and hydroxychloroquine non-recipients were those managed with standard of care alone.

Results Of 150 patients, 148 had mild to moderate disease and two had severe disease. The mean duration from symptom onset to randomisation was 16.6 (SD 10.5; range 3-41) days. A total of 109 (73%) patients (56 standard of care; 53 standard of care plus hydroxychloroquine) had negative conversion well before 28 days, and the remaining 41 (27%) patients (19 standard of care; 22 standard of care plus hydroxychloroquine) were censored as they did not reach negative conversion of virus. The probability of negative conversion by 28 days in the standard of care plus hydroxychloroquine group was 85.4% (95% confidence interval 73.8% to 93.8%), similar to that in the standard of care group (81.3%, 71.2% to 89.6%). The difference between groups was 4.1% (95% confidence interval –10.3% to 18.5%). In the safety population, adverse events were recorded in 7/80 (9%) hydroxychloroquine non-recipients and in 21/70 (30%) hydroxychloroquine recipients. The most common adverse event in the hydroxychloroquine recipients was diarrhoea, reported in 7/70 (10%) patients. Two hydroxychloroquine recipients reported serious adverse events.

Conclusions Administration of hydroxychloroquine did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate covid-19. Adverse events were higher in hydroxychloroquine recipients than in non-recipients.

Trial registration ChiCTR2000029868." />
<meta name="og-type" property="og:type" content="article" />
<meta name="og:image" property="og:image" content="https://www.bmj.com/sites/default/files/highwire/bmj/383/8403.cover-source.jpg"/>
<meta name="twitter:card" content="summary_large_image"><meta name="twitter:image" property="twitter:image" content="https://www.bmj.com/sites/default/files/sites/defautl/files/attachments/bmj-article/2020/05/hydroxychloroquinine_2.jpg"><meta name="twitter:title" content="Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial" /><meta name="generator" content="Drupal 7 (http://drupal.org)" />
<link rel="canonical" href="https://www.bmj.com/content/369/bmj.m1849" />
<link rel="shortlink" href="https://www.bmj.com/node/1027155" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:url" content="https://www.bmj.com/content/369/bmj.m1849" />
<meta name="twitter:title" content="Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial" />
  <title>Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial | The BMJ</title>

  <!--[if lte IE 9]>
    <link href="/sites/default/themes/bmj/the_bmj/css/ie.css" rel="stylesheet" media="all" type="text/css">
    <link href="/sites/default/themes/bmj/the_bmj/css/ie_2.css" rel="stylesheet" media="all" type="text/css">
    <link href="/sites/default/themes/bmj/the_bmj/css/ie_3.css" rel="stylesheet" media="all" type="text/css">
    <link href="/sites/default/themes/bmj/the_bmj/css/bootstrap-ie7.css" rel="stylesheet” media="all" type="text/css">
  <![endif]-->
  <!--[if IEMobile]>
      <link href="/sites/default/themes/bmj/the_bmj/css/screen.css" rel="stylesheet" media="all" type="text/css">
      <link href="/sites/default/themes/bmj/the_bmj/css/screen_2.css" rel="stylesheet" media="all" type="text/css">
      <link href="/sites/default/themes/bmj/the_bmj/css/screen_3.css" rel="stylesheet" media="all" type="text/css">     
  <![endif]-->
  <link type="text/css" rel="stylesheet" href="https://www.bmj.com/sites/default/files/advagg_css/css__FiHqHoPUdv6CHw5dUEIfFV7jpYTgBb1JUncssjaxHyo__WrmpJPOLcBtgZvbeHlOvj5PoBuoB3ROCf1SvZY3flT4__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.css" media="all" />
<link type="text/css" rel="stylesheet" href="//cdn.jsdelivr.net/qtip2/2.2.1/jquery.qtip.min.css" media="all" />
<link type="text/css" rel="stylesheet" href="https://www.bmj.com/sites/default/files/advagg_css/css__UVdBeXn2OJuHSo2uOe0p81MBuxOZ0FoYwlaDP2Agywo__yxCvgm9y2Tvx_5ljn9VCDIsWkgDkNV3fLoCbSdh55KY__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.css" media="all" />
<link type="text/css" rel="stylesheet" href="https://www.bmj.com/sites/default/files/advagg_css/css__hcEfBsSfdZ2na-rT9Jhk7K2mHyy5KBdPKm6ia_F7MYU__4716zpuGoj4DfVIEENbeOWgAOX_pf_t16EI4fvJGo7A__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.css" media="print" />
<link type="text/css" rel="stylesheet" href="https://www.bmj.com/sites/default/files/advagg_css/css__b-tWEqg3_twqP_ufdNXyA5V14StJgBdiIxG1UIi0LYc__ofNN3Tm1kOUkUdILy3fLSa1EGB-MBI6UD9ySd1HlqdM__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.css" media="screen" />
<link type="text/css" rel="stylesheet" href="https://www.bmj.com/sites/default/files/advagg_css/css__-BkZ71IF4pBXmZfP4vYyswWdIhuaKktrUUQ4i2vtUVo__0i_0YcYkMECNn0z7FdhNoJ8gLWleqnTtjnHRAmLijvc__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.css" media="all" />
  <link href="/sites/default/themes/bmj/the_bmj/css/fonts.css" rel="stylesheet" media="all" type="text/css">

   <style media="screen" type="text/css">
       .page-news #latest-blogs h2.pane-title, .bootstrap-threecol-4-4-4 #latest-blogs h2.pane-title {
            width: 153px !important;
        }
        #navigation-wrapper #navigation .main-navigation .menu.nav>li.last {
          display: block !important;
        }
    </style>

    <!-- TCF stub -->
    <script src="https://cdn.cookielaw.org/consent/tcf.stub.js"" type="text/javascript" charset="UTF-8"></script>

    <!-- OneTrust Cookies Consent Notice start -->
    <script src="https://cookie-cdn.cookiepro.com/scripttemplates/otSDKStub.js"  type="text/javascript" charset="UTF-8" data-domain-script="565e50dd-f6e9-46d6-91cd-5c40a270264f"></script>

    <script type="text/javascript">

      function OnetrustAdsConsent(){
          if(googletag.apiReady){
            //console.log("GoogleTag API ready")
            googletag.pubads().disableInitialLoad();
          
            if(OptanonActiveGroups.match(/,4,/)){
              googletag.pubads().setRequestNonPersonalizedAds(0);
              //googletag.pubads().refresh();
            }
            else{
              googletag.pubads().setRequestNonPersonalizedAds(1);
             // googletag.pubads().refresh();
            }
          }
          else{
          OnetrustAdsConsent();
        }   
      }

      function OptanonWrapper() {
        OnetrustAdsConsent();
  }
    </script>
    <!-- OneTrust Cookies Consent Notice end -->

  <script src="https://www.bmj.com/sites/default/files/advagg_js/js__V5zEWkEksIWK6VINPUHu3OynhhS1mnYIclPfddCUPtE__jX8UWRvGaqQAvFnLHOQmoaSahn6jelSksGgbPsAQgxU__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.js"></script>
<script src="//cdn.jsdelivr.net/qtip2/2.2.1/jquery.qtip.min.js"></script>
<script src="https://www.bmj.com/sites/default/files/advagg_js/js__GVXoElgzP4KkFOACVyanginF0YtUpDQqYZa4Yak2Vk0__8rEHJ8-XPKZutMaIVL6U77BOKPKN1pUuh9QhofoKxm8__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.js"></script>
<script src="https://www.bmj.com/sites/default/files/advagg_js/js__eWf-vBAqoxYf47645tT27coIWA8vlfpfKIm_CFwiPpI__-iUShiY3pXhRQ15t9Brbnlwcyh1Ob6nu8HcdW8yDxTQ__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.js"></script>
<script src="https://www.bmj.com/sites/default/files/advagg_js/js__CddA4xWkENACJ8XizNGQ2xZD888b8fMc69y8dWbxaqE__gAU5_ak50lnwB_AHXvbI70lsOBzR7PL9azY3KoLjV0A__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.js"></script>
<script src="https://www.google.com/recaptcha/api.js?hl=en&amp;render=explicit&amp;onload=drupalRecaptchaOnload"></script>
<script src="https://www.bmj.com/sites/default/files/advagg_js/js__67c2rIWioL3jmSb7cEu0fAzEz7iPlKnuw0INmpvbBow__LD4LlXHOHVJuxywL1qilPFSc4EiN7Zdr-tf_j7z_lTQ__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.js"></script>
<script>var _prum=[['id', '612e3f1b1733500011000061'], ['mark', 'firstbyte',
      (new Date()).getTime()]]; (function() {
      var s=document.getElementsByTagName('script')[0],
      p=document.createElement('script');
      p.async='async'; p.src='//rum-static.pingdom.net/prum.min.js';s.parentNode.insertBefore(p,s);})();</script>
<script>if(typeof window.MathJax === "undefined") window.MathJax = { menuSettings: { zoom: "Click" } };</script>
<script async="async" src="https://scholar.google.com/scholar_js/casa.js"></script>
<script>jQuery.extend(Drupal.settings,{"basePath":"\/","pathPrefix":"","ajaxPageState":{"theme":"the_bmj","theme_token":"R4XTtQwRUnLOIjwG4M2L3VzbWtptR8Uzw8pJJprLIiA"},"colorbox":{"opacity":"0.85","current":"{current} of {total}","previous":"\u00ab Prev","next":"Next \u00bb","close":"Close","maxWidth":"98%","maxHeight":"98%","fixed":true,"mobiledetect":true,"mobiledevicewidth":"480px"},"highwire":{"nid":"1027155","apath":"\/bmj\/369\/bmj.m1849.atom","pisa":"bmj;369\/may14_5\/m1849","ac":{"\/bmj\/369\/bmj.m1849.atom":{"access":{"full":true,"reprint":true},"pisa_id":"","apath":"\/bmj\/369\/bmj.m1849.atom","jcode":"bmj"}},"processed":["highwire_math"],"markup":[{"requested":"long","variant":"full-text","view":"full","pisa":"bmj;369\/may14_5\/m1849"},{"requested":"index","variant":"index","view":"full","pisa":"bmj;bmj.m1849\/DC1"},{"requested":"index","variant":"index","view":"full","pisa":"bmj;bmj.m1849\/DC1"}],"trendmd":{"trendmd-suggestions":"{\u0022element\u0022:\u0022#trendmd-suggestions\u0022,\u0022track_id\u0022:\u002224814\u0022}"}},"jnl_bmj_infographic":{"infographic_tab":false},"custom_search":{"form_target":"_self","solr":1},"panel_ajax_tab":{"path":"sites\/all\/modules\/contrib\/panels_ajax_tab"},"instances":"{\u0022highwire_abstract_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:20,\u0022height\u0022:20,\u0022border\u0022:1,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-abstract-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022right center\u0022,\u0022my\u0022:\u0022left center\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022shift\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter click \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}},\u0022highwire_author_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:15,\u0022height\u0022:15,\u0022border\u0022:1,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-author-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022top center\u0022,\u0022my\u0022:\u0022bottom center\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}},\u0022highwire_reflinks_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:15,\u0022height\u0022:15,\u0022border\u0022:1,\u0022mimic\u0022:\u0022top center\u0022,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-ref-link-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022bottom left\u0022,\u0022my\u0022:\u0022top left\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022flip\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}}}","qtipDebug":"{\u0022leaveElement\u0022:0}","ws_fl":{"width":100,"height":21},"jnl_bmj":{"container_id_share":"article-share-modal","container_id_response":"article-response-modal"},"urlIsAjaxTrusted":{"\/content\/369\/bmj.m1849?tab=article-alert":true,"\/content\/369\/bmj.m1849":true,"\/login":true},"orcidLogo":{"svg":"\/sites\/default\/themes\/bmj\/the_bmj\/img\/vector_iD_icon.svg"},"bootstrap":{"anchorsFix":"1","anchorsSmoothScrolling":"1","popoverEnabled":"1","popoverOptions":{"animation":1,"html":0,"placement":"right","selector":"","trigger":"click","title":"","content":"","delay":0,"container":"body"},"tooltipEnabled":"1","tooltipOptions":{"animation":1,"html":0,"placement":"auto left","selector":"","trigger":"hover focus","delay":0,"container":"body"}}});</script>

    <script type="text/javascript">
        window.dataLayer = window.dataLayer || [];
    </script>

    <!-- GTM custom dimensions -->
  <script type="text/javascript">var DC = { Date : "", subject : "" };var ga_article_category = "Research";var ga_article_page_type = "research-article";var ga_article_pub_year = "2020";var ga_customer_number = "";var ga_user_type = "";DC.Date = "2020-05-14";DC.subject = "";</script>  <!-- End GTM custom dimensions -->

    <!-- Optimize Page Hiding Snippet -->
    <style>.async-hide { opacity: 0 !important} </style>
    <script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date; h.end=i=function(){s.className=s.className.replace(RegExp(' ?'+y),'')}; (a[n]=a[n]||[]).hide=h;setTimeout(function(){i();h.end=null},c);h.timeout=c;})(window,document.documentElement,'async-hide','dataLayer',4000,{'GTM-NF7HCLL':true});</script>
    <!-- end Optimize Page Hiding Snippet -->

    <!-- Start GPT Tag -->
    <script>var googletag = window.googletag || {cmd: []};</script>
    <script async src="//securepubads.g.doubleclick.net/tag/js/gpt.js"></script>
        <script>
            var topBottomSizes = [
              [970,250],[970,90],[728,90],[468,60],[300,50],[320,100]
            ];
            var mpuSizes = [
              [300,250],[300,600],[600,600],
            ];
//googletag.cmd.push(function() { googletag.display('div-gpt-ad-7326006-1'); });
    googletag.cmd.push(function() {
      googletag.defineSlot('/21798771943/BMJ.com_HomePage_TOPBanner', topBottomSizes,'div-gpt-ad-7326006-1').addService(googletag.pubads()).setTargeting("pgid", "pubgrade_lib_disabled");
      googletag.defineSlot('/21798771943/BMJ.com_HomePage_MPU1', mpuSizes, 'div-gpt-ad-7326006-2').addService(googletag.pubads());
      googletag.defineSlot('/21798771943/BMJ.com_HomePage_MPU2', mpuSizes, 'div-gpt-ad-7326006-3').addService(googletag.pubads());
      googletag.defineSlot('/21798771943/BMJ.com_HomePage_BOTTOM', topBottomSizes, 'div-gpt-ad-7326006-4').addService(googletag.pubads());
      googletag.pubads().setTargeting('url', window.parent.location.pathname);

      // Some examples of ways to enable below. Normally, only one of these
      // methods should be used.

      // A) Enable with defaults.
      //googletag.pubads().enableLazyLoad({
      //fetchMarginPercent: 0,  // Fetch slots within 1 viewports.
      //renderMarginPercent: 0,  // Render slots within 1 viewports.
      //mobileScaling: 2.0  // Double the above values on mobile.
      //});
      googletag.enableServices();
  });
    </script>
    <!-- End GPT Tag -->

  <!-- Google Tag Manager -->
  <script type="text/javascript">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0];var j=d.createElement(s);var dl=l!='dataLayer'?'&l='+l:'';j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;j.type='text/javascript';j.async=true;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-NF7HCLL');</script>
  <!-- End Google Tag Manager -->

</head>
<!--[if IE 6]><div class="ie-warning">Our New BMJ website does not support IE6 please upgrade your browser to the latest version or use alternative browsers suggested below.
<ul>
<li>- Google Chrome</li>
<li>- Safari</li>
<li>- Firefox</li>
</ul>
</div>
<![endif]-->
<body class="html not-front not-logged-in no-sidebars page-node page-node- page-node-1027155 node-type-highwire-article 1 Research" >

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-NF7HCLL" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->

  <div id="skip-link">
    <a href="#main-content" class="element-invisible element-focusable">Skip to main content</a>
  </div>
    <div id="wrapper-outer">
    <div id="wrapper">
        <header>

           <div class="bmj-disclaimer">
                <p>Intended for healthcare professionals</p>
            </div>

            <div class="ad-leaderboard">
                <div id='div-gpt-ad-7326006-1'>
                    <script>
                        googletag.cmd.push(function() { googletag.display('div-gpt-ad-7326006-1'); });
                    </script>
                </div>
            </div>


            <!-- NAVIGATION -->
            <!-- Top Navigation -->
            <div id="top-nav" role="navigation" class="navbar navbar-static-top">
                <div class="container">
                    <div id="userbar-status">
                        <ul id="status">
                            
    <li class="user-status-link user-status-subscribe phone-menu-item">
        <a href="/us/subscribe">Subscribe</a>
    </li>

<li class="user-status-myaccount phone-menu-item">
    
<div class="btn-group has-submenu">
  <a class="btn dropdown-toggle" aria-expanded="false" aria-haspopup="true" data-toggle="dropdown" href="#" >
    My Account    <span class="caret" aria-expanded="true"></span>
  </a>
  <ul class="jnl-bmj-user-my-account dropdown-menu"><li class="0 first last"><a href="//myaccount.bmj.com/myaccount/account/hw-registration.html">My email alerts</a></li>
</ul></div>
</li>

    <li class="user-status-bma phone-menu-item">
        <a href="//bmjverification.bma.org.uk/validate/userdetails?url=https://www.bmj.com/content/369/bmj.m1849?sso=">BMA member login</a>
    </li>
                                
<div class="btn-group has-submenu">
  <a class="btn dropdown-toggle" aria-expanded="false" aria-haspopup="true" data-toggle="dropdown" href="#" >
    Login    <span class="caret" aria-expanded="true"></span>
  </a>
  <ul class="jnl-bmj-user-signin-popup dropdown-menu"><li class="0 first last"><span><form action="/login" method="post" id="jnl-bmj-user-login-form" accept-charset="UTF-8"><div><input type="hidden" name="form_build_id" value="form-2r_J6HBSQzEzSTiq9qKzzB-S8XMS0xv5T12QIB-IrR0" />
<input type="hidden" name="form_id" value="jnl_bmj_user_login_form" />
<div class="form-type-textfield form-item-name form-item form-group">
  <label for="article-p-name">Username <span class="form-required" title="This field is required.">*</span></label>
 <input class="form-control form-text required" type="text" id="article-p-name" name="name" value="" size="15" maxlength="60" />
</div>
<div class="form-type-password form-item-pass form-item form-group">
  <label for="article-p-pass">Password <span class="form-required" title="This field is required.">*</span></label>
 <input class="form-control form-text required" type="password" id="article-p-pass" name="pass" size="15" maxlength="128" />
</div>
<div class="link"><div id="edit-forgot" class="form-type-item form-item form-group">
  <label for="edit-forgot"><a href="https://www.bmj.com/user/password" title="Retrieve your credentials.">Forgot your log in details?</a> </label>
 
</div>
</div><div class="link"><div id="edit-activate" class="form-type-item form-item form-group">
  <label for="edit-activate"><a href="//journals.bmj.com/cgi/activate/basic">Need to activate</a> </label>
 
</div>
</div><input class="btn form-submit" type="submit" id="edit-submit--8" name="op" value="Login" /><div id="edit-message" class="form-type-item form-item form-group">
  
</div>
<hr /><div id="edit-bma-members" class="form-type-item form-item form-group">
  <label for="edit-bma-members"><a href="//bmjverification.bma.org.uk/validate/userdetails?url=https%3A//www.bmj.com/content/369/bmj.m1849%3Fsso%3D" title="Log in here if you are a BMA member.">BMA Member Log In</a> </label>
 
</div>
<div id="edit-athens" class="form-type-item form-item form-group">
  <label for="edit-athens"><a href="https://openathens-sp.highwire.org/session/init?entityID=https%3A//idp.eduserv.org.uk/openathens&amp;subcode=bmjjournals&amp;hw-shib-return-uri=https%253A%252F%252Fwww.bmj.com%252Fcontent%252F369%252Fbmj.m1849">Log in via OpenAthens</a> </label>
 
</div>
<div id="edit-shibboleth" class="form-type-item form-item form-group">
  <label for="edit-shibboleth"><a href="/login/shibboleth?uri=https%3A%2F%2Fwww.bmj.com%2Fcontent%2F369%2Fbmj.m1849&amp;subcode=bmjjournals&amp;env=prod">Log in via your institution</a> </label>
 
</div>
</div></form></span></li>
</ul></div>
                        </ul><!-- /status -->
                                                    <div id="userbar">
                                  <div class="region region-userbar">
    <section id="block-panels-mini-jnl-bmj-country-portal-switcher" class="block block-panels-mini clearfix">

      
  <div class="panel-display panel-1col clearfix" id="mini-panel-jnl_bmj_country_portal_switcher">
  <div class="panel-panel panel-col">
    <div><div class="panel-pane pane-country-switcher"  >
  
      
  
  <div class="pane-content">
    <span class="country-label">Edition: </span>
<div class="btn-group has-submenu">
  <a class="btn dropdown-toggle" aria-expanded="false" aria-haspopup="true" data-toggle="dropdown" href="#" id=country-switcher>
    US    <span class="caret" aria-expanded="true"></span>
  </a>
  <ul class="jnl-bmj-country-portal-country-switcher  dropdown-menu"><li class="0 first"><a href="/bmj_countries/switch/uk?destination=node/1027155">UK</a></li>
<li class="1"><a href="/bmj_countries/switch/india?destination=node/1027155">South Asia</a></li>
<li class="2 last"><a href="/bmj_countries/switch/international?destination=node/1027155">International</a></li>
</ul></div>
  </div>

  
  </div>
</div>
  </div>
</div>

</section> <!-- /.block -->
  </div>
                            </div><!-- /userbar -->
                        
                        <div id="cmp-link">
                            <div class="pane-content">
                                <span class="country-label"><a href="/company?int_source=tbmj&int_medium=header&int_campaign=URLswitch">Our company</a></span>
                            </div>
                        </div>

                    </div><!-- /userbar-status -->
                </div><!-- /container -->
            </div><!-- /top-nav -->

            <!-- Main Navigation -->
            <div id="main-nav" data-spy="affix" data-offset-top="125">
                <div class="primary-navigation-bar">
                    <div id="navigation-wrapper">

                        <div class="container">
                            <!-- Navigation toggle -->
                            <a href="#" id="btn-nav" class="">
                                <span class="sr-only">Toggle navigation</span>
                            </a>
                            <!-- Logo -->
                                                            <a class="logo navbar-btn pull-left" href="/" title="Home">
                                    <!-- <img src="https://www.bmj.com/sites/default/themes/bmj/the_bmj/logo.png" alt="Home" /> -->
                                    <div class="bmj-logo">The BMJ logo</div>
                                </a>
                                                        <div class="ie6-site-map"><a href="/sitemap">Site map</a></div>
                            <!-- Search -->
                            <div class="main-nav-search">
                                <div id="search">
                                    <!--<span class="glyphicon glyphicon-search"></span>-->
                                    <a href="#" class="dropdown-toggle" data-toggle="dropdown" title="Search"><div class="search"><em class="fa fa-search" alt="Search"></em><span class="search-label">Search</span></div></a>
                                    <div class="dropdown-menu">
                                        <div class="header-search-form container">
                                            <div class="searchbar">
                                                                                                      <div class="region region-search-block">
    <section id="block-search-form" class="block block-search clearfix">

      
  <form class="search-form form-search content-search" action="/content/369/bmj.m1849" method="post" id="search-block-form" accept-charset="UTF-8"><div><div>
      <h2 class="element-invisible">Search form</h2>
    <div class="input-group"><input title="Enter the terms you wish to search for." class="container-inline input-append form-control form-text" placeholder="Search The BMJ" type="text" id="edit-search-block-form--2" name="search_block_form" value="" size="15" maxlength="128" /><span class="input-group-btn"><button type="submit" class="btn btn-default">Search</button></span></div><button  class="element-invisible btn btn-primary btn btn-primary form-button" type="submit" id="edit-submit--3" name="op" value="Search">Search</button><input type="hidden" name="form_build_id" value="form-Mi6NfSevok3oZGKhcJXMV_oEbJ4zSk8WH0bdJQx65vQ" />
<input type="hidden" name="form_id" value="search_block_form" />
<input type="hidden" name="custom_search_paths" value="search/advanced/[key]" />
</div>
</div></form>
</section> <!-- /.block -->
  </div>
                                                                                            </div>

                                            <div class="advanced-search">
                                                <ul class="list-inline">
                                                    <li><a href="/search/advanced" title="Advanced search">Advanced search</a></li>
                                                    <li><a href="/rapid-responses" title="Search responses">Search responses</a></li>
                                                    <li><a href="//blogs.bmj.com/bmj/" title="Search blogs">Search blogs</a></li>
                                                </ul>
                                            </div><!-- /advanced-search -->
                                        </div><!-- /header-search-form -->
                                    </div><!-- /dropdown-menu -->
                                </div><!-- /search -->
                            </div><!-- /main-nav-search -->

                            <!-- Mobile top nav -->
                            <a href="#" id="toggle-mobile-top-nav">
                                <span class="fa fa-cog"></span>
                                <span class="sr-only">Toggle top menu</span>
                            </a>

                            <!-- Navigation -->
                            <div id="navigation" class="navigation">
                                <!-- Main Navigation -->
                                <div class="main-navigation">
                                                                        <nav role="navigation">
                                    
                                                                                    <ul class="menu nav navbar-nav"><li class="first leaf"><a href="/coronavirus">covid-19</a></li>
<li class="expanded dropdown"><a href="/us/research" data-target="#" class="dropdown-toggle" data-toggle="dropdown">Research</a><ul class="dropdown-menu"><li class="first leaf"><a href="/us/research">At a glance</a></li>
<li class="leaf"><a href="/us/research/research">Research papers</a></li>
<li class="leaf"><a href="/us/research/research%20methods%20%26amp%3B%20reporting">Research methods and reporting</a></li>
<li class="leaf"><a href="/us/research/minerva">Minerva</a></li>
<li class="last leaf"><a href="/us/research/research%20news">Research news</a></li>
</ul></li>
<li class="expanded dropdown"><a href="/us/education" data-target="#" class="dropdown-toggle" data-toggle="dropdown">Education</a><ul class="dropdown-menu"><li class="first leaf"><a href="/us/education">At a glance</a></li>
<li class="leaf"><a href="/us/education/clinical%20review">Clinical reviews</a></li>
<li class="leaf"><a href="/us/education/practice">Practice</a></li>
<li class="leaf"><a href="/us/education/minerva">Minerva</a></li>
<li class="leaf"><a href="/us/education/endgames">Endgames</a></li>
<li class="leaf"><a href="/specialties/state-art">State of the art</a></li>
<li class="leaf"><a href="/specialties/what-your-patient-thinking">What your patient is thinking</a></li>
<li class="leaf"><a href="/rapid-recommendations">Rapid recommendations</a></li>
<li class="last leaf"><a href="/student">Student</a></li>
</ul></li>
<li class="expanded dropdown"><a href="/us/news" data-target="#" class="dropdown-toggle" data-toggle="dropdown">News & Views</a><ul class="dropdown-menu"><li class="first leaf"><a href="/us/news">At a glance</a></li>
<li class="leaf"><a href="/us/news/news?category=News">News</a></li>
<li class="leaf"><a href="/us/news/feature">Features</a></li>
<li class="leaf"><a href="/us/news/editorial">Editorials</a></li>
<li class="leaf"><a href="/us/news/analysis">Analysis</a></li>
<li class="leaf"><a href="/us/news/observations">Observations</a></li>
<li class="leaf"><a href="/news/opinion">Opinion</a></li>
<li class="leaf"><a href="/us/news/head%20to%20head">Head to head</a></li>
<li class="leaf"><a href="/us/news/editor%27s%20choice">Editor&#039;s choice</a></li>
<li class="leaf"><a href="/us/news/letter">Letters</a></li>
<li class="leaf"><a href="/us/news/obituary">Obituaries</a></li>
<li class="leaf"><a href="/us/news/views%20%26amp%3B%20reviews">Views and reviews</a></li>
<li class="leaf"><a href="/careers-articles">Careers</a></li>
<li class="last leaf"><a href="/rapid-responses">Rapid responses</a></li>
</ul></li>
<li class="expanded dropdown"><a href="/campaigns" data-target="#" class="dropdown-toggle" data-toggle="dropdown">Campaigns</a><ul class="dropdown-menu"><li class="first leaf"><a href="/campaigns">At a glance</a></li>
<li class="leaf"><a href="/better-evidence">Better evidence</a></li>
<li class="leaf"><a href="/campaign/climate-emergency">Climate change</a></li>
<li class="leaf"><a href="/divestment">Divestment from fossil fuels</a></li>
<li class="leaf"><a href="/campaign/patient-partnership">Patient and public partnership</a></li>
<li class="leaf"><a href="/too-much-medicine">Too much medicine</a></li>
<li class="last leaf"><a href="/wellbeing">Wellbeing</a></li>
</ul></li>
<li class="last expanded dropdown"><a href="/careers" data-target="#" class="dropdown-toggle" data-toggle="dropdown">Jobs</a><ul class="dropdown-menu"><li class="first leaf"><a href="/careers">Doctor Jobs UK</a></li>
<li class="leaf"><a href="/careers/jobs/hospital/">Hospital Jobs UK</a></li>
<li class="leaf"><a href="/careers/jobs/general-practice/">GP Jobs UK</a></li>
<li class="last leaf"><a href="/careers/jobs/international/">International Jobs</a></li>
</ul></li>
</ul>                                        
                                        <!-- Second Navigation -->
                                        <div class="second-navigation">
                                            <ul class="secondary-nav" id="">
                                                <li class="even"><a href="/archive" class="">Archive</a></li>
                                                <li class="odd"><a href="/about-bmj/resources-authors" class="">For authors</a></li>
                                                <li class="odd last"><a href="http://hosted.bmj.com" class="">Hosted</a></li>
                                            </ul>
                                        </div><!-- /second-navigation -->
                                    </nav>
                                </div><!-- /main-navigation -->

                                                            </div><!-- /navigation -->




                        </div><!-- /container -->
                    </div><!-- /navigation-wrapper -->
                </div><!-- /navbar navbar-default navbar-fixed-top -->
            </div><!-- Main nav -->
        </header><!-- /header -->

        <div class="main-container container" id="page"> <!-- #page is for back to top to work -->
            <!-- Remove heading -->
            <div class="row">
                
                <section  class="col-sm-12" >
                                        <ol class="breadcrumb"><li class="first"><a href="/us/research">Research</a></li>
<li>Hydroxychloroquine in...</li>
<li class="active last">Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial</li>
</ol>                    <a id="main-content"></a>

                                        
                                                                                                                                                                                          <div class="region region-content">
    <section id="block-system-main" class="block block-system clearfix">

      
  <div class="panel-display" >
  <div class="hero"> <div class="panel-pane pane-bmj-article-open-access"  >
  
      
  
  <div class="pane-content">
    <div class="creative-commons" title="Creative Commons"><span class="creative-commons-article"><span class="icon-cc">CC</span><span class="icon-by">BY</span> <span>Open access</span></span></div>  </div>

  
  </div>
    <div class="hero-wrapper">
      <div class="hero-content" style="position: relative; left: 0px; top: 35.5px;">  </div>
      <!-- hero-content -->
    </div>
    <!-- hero-wrapper -->
  </div>
  <!-- hero -->

  <div class="row">
      <div class="left-content col-xs-12 col-sm-8 col-md-8 col-lg-8">
        <article>
          <div class="panel-pane pane-highwire-article-citation"  >
  
      
  
  <div class="pane-content">
    <div class="highwire-article-citation highwire-citation-type-highwire-article node1027155" data-node-nid="1027155" id="node-1027155--2488994411" data-pisa="bmj;369/may14_5/m1849" data-pisa-master="bmj;bmj.m1849" data-apath="/bmj/369/bmj.m1849.atom"><cite class='highwire-cite highwire-citation-bmj-article-top'>

            <span class='highwire-cite-article-type'>Research</span>
    
    
            <h1 class="highwire-cite-title" id="page-title">Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial</h1>    
    <span class='highwire-cite-journal'>BMJ</span>
    <span class='highwire-cite-published-year'>2020</span>;
    <span class='highwire-cite-volume-issue'>369</span>
    <span class='highwire-cite-doi'> doi: <a href="https://doi.org/10.1136/bmj.m1849">https://doi.org/10.1136/bmj.m1849</a></span>
    <span class='highwire-cite-date'>(Published 14 May 2020)</span>
  <span class='highwire-cite-article-as'>
    Cite this as: <span
          class="italic">BMJ</span> 2020;369:m1849  </span>

            <span class='sound-cloud'><a href="https://www.bmj.com/coronavirus" style="color:#FFFFFF;" target="new">
<div style="background-color: #2A6EBB; width 200px; padding: 10px; border-radius: 5px; margin: 15px 0px">
<h2 style="color: #FFFFFF;">Read our latest coverage of the coronavirus pandemic</h2>
</div>
</a>
<a href="https://www.bmj.com/content/369/bmj.m2018" style="color:#FFFFFF;" target="new">
<div style="background-color: #2A6EBB; width 200px; padding: 10px; border-radius: 5px; margin: 15px 0px">
<h2 style="color: #FFFFFF;">Linked Editorial</h2>
<p style="margin-bottom: 0px;">Lack of efficacy of hydroxychloroquine in covid-19</p>
</div>
</a></span>
    
    
</cite>
</div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-panel-tabs pane-panels-ajax-tab-tabs"  >
  
      
  
  <div class="pane-content">
    <ul class="tabs inline panels-ajax-tab"><li class="first"><a title="Article Tab - Article" href="/content/369/bmj.m1849" class="panels-ajax-tab-tab" data-panel-name="jnl_bmj_tab_art" data-target-id="highwire_article_tabs" data-entity-context="node:1027155" data-trigger="" data-url-enabled="1"><span>Article</span></a><a title="Article Tab - Article" href="/panels_ajax_tab/jnl_bmj_tab_art/node:1027155/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li>
<li><a title="Article Tab - Related Articles" href="/content/369/bmj.m1849/related" class="panels-ajax-tab-tab" data-panel-name="jnl_bmj_tab_related_art" data-target-id="highwire_article_tabs" data-entity-context="node:1027155" data-trigger="related" data-url-enabled="1"><span>Related content</span></a><a title="Article Tab - Related Articles" href="/panels_ajax_tab/jnl_bmj_tab_related_art/node:1027155/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li>
<li><a title="Article Tab - Info & Metrics" href="/content/369/bmj.m1849/article-info" class="panels-ajax-tab-tab" data-panel-name="jnl_bmj_tab_info" data-target-id="highwire_article_tabs" data-entity-context="node:1027155" data-trigger="article-info" data-url-enabled="1"><span>Metrics</span></a><a title="Article Tab - Info & Metrics" href="/panels_ajax_tab/jnl_bmj_tab_info/node:1027155/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li>
<li><a title="BMJ Article Related Rapid Responses" href="/content/369/bmj.m1849/rapid-responses" class="panels-ajax-tab-tab" data-panel-name="bmj_related_rapid_responses" data-target-id="highwire_article_tabs" data-entity-context="node:1027155" data-trigger="rapid-responses" data-url-enabled="1"><span>Responses</span></a><a title="BMJ Article Related Rapid Responses" href="/panels_ajax_tab/bmj_related_rapid_responses/node:1027155/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li>
<li><a title="Article Tab - Peer review" href="/content/369/bmj.m1849/peer-review" class="panels-ajax-tab-tab" data-panel-name="jnl_bmj_tab_peer_review" data-target-id="highwire_article_tabs" data-entity-context="node:1027155" data-trigger="peer-review" data-url-enabled="1"><span>Peer review</span></a><a title="Article Tab - Peer review" href="/panels_ajax_tab/jnl_bmj_tab_peer_review/node:1027155/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li>
<li class="last"><a title="BMJ Rapid Responses Form" href="/content/369/bmj.m1849/submit-a-rapid-response" class="panels-ajax-tab-tab" data-panel-name="bmj_rapid_responses_form" data-target-id="highwire_article_tabs" data-entity-context="node:1027155" data-trigger="submit-a-rapid-response" data-url-enabled="1"><i class="fa fa-edit"></i></a><a title="BMJ Rapid Responses Form" href="/panels_ajax_tab/bmj_rapid_responses_form/node:1027155/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li>
</ul>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-panel-tabs-container"  >
  
      
  
  <div class="pane-content">
    <div data-panels-ajax-tab-preloaded="jnl_bmj_tab_art" id="panels-ajax-tab-container-highwire_article_tabs" class="panels-ajax-tab-container"><div class="panels-ajax-tab-loading" style ="display:none"><img class="loading" src="https://www.bmj.com/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif" alt="Loading" title="Loading" /></div><div class="panels-ajax-tab-wrap-jnl_bmj_tab_art"><div class="panel-display panel-1col clearfix" >
  <div class="panel-panel panel-col">
    <div><div class="panel-pane pane-highwire-markup"  >
  
      
  
  <div class="pane-content">
    <div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml" data-highwire-cite-ref-tooltip-instance="highwire_reflinks_tooltip" class="content-block-markup" xmlns:xhtml="http://www.w3.org/1999/xhtml"><div class="article fulltext-view "><span class="highwire-journal-article-marker-start"></span><div class="contributors"><ol class="contributor-list" id="contrib-group-1"><li class="contributor" id="contrib-1"><span class="name">Wei Tang</span><span class="contrib-role">, associate professor</span><a id="xref-aff-1-1" class="xref-aff" href="#aff-1">1 </a><a id="xref-aff-2-1" class="xref-aff" href="#aff-2">2</a>, </li><li class="contributor" id="contrib-2"><span class="name">Zhujun Cao</span><span class="contrib-role">, infectious diseases physician</span><a id="xref-aff-3-1" class="xref-aff" href="#aff-3">3</a>, </li><li class="contributor" id="contrib-3"><span class="name">Mingfeng Han</span><span class="contrib-role">, chest physician</span><a id="xref-aff-4-1" class="xref-aff" href="#aff-4">4</a>, </li><li class="contributor" id="contrib-4"><span class="name">Zhengyan Wang</span><span class="contrib-role">, chest physician</span><a id="xref-aff-5-1" class="xref-aff" href="#aff-5">5</a>, </li><li class="contributor" id="contrib-5"><span class="name">Junwen Chen</span><span class="contrib-role">, chest physician</span><a id="xref-aff-6-1" class="xref-aff" href="#aff-6">6</a>, </li><li class="contributor" id="contrib-6"><span class="name">Wenjin Sun</span><span class="contrib-role">, infectious diseases physician</span><a id="xref-aff-7-1" class="xref-aff" href="#aff-7">7</a>, </li><li class="contributor" id="contrib-7"><span class="name">Yaojie Wu</span><span class="contrib-role">, cardiovascular physician</span><a id="xref-aff-8-1" class="xref-aff" href="#aff-8">8</a>, </li><li class="contributor" id="contrib-8"><span class="name">Wei Xiao</span><span class="contrib-role">, chest physician</span><a id="xref-aff-9-1" class="xref-aff" href="#aff-9">9</a>, </li><li class="contributor" id="contrib-9"><span class="name">Shengyong Liu</span><span class="contrib-role">, infectious diseases physician</span><a id="xref-aff-10-1" class="xref-aff" href="#aff-10">10</a>, </li><li class="contributor" id="contrib-10"><span class="name">Erzhen Chen</span><span class="contrib-role">, professor</span><a id="xref-aff-11-1" class="xref-aff" href="#aff-11">11</a>, </li><li class="contributor" id="contrib-11"><span class="name">Wei Chen</span><span class="contrib-role">, chest physician</span><a id="xref-aff-1-2" class="xref-aff" href="#aff-1">1 </a><a id="xref-aff-2-2" class="xref-aff" href="#aff-2">2</a>, </li><li class="contributor" id="contrib-12"><span class="name">Xiongbiao Wang</span><span class="contrib-role">, chest physician</span><a id="xref-aff-12-1" class="xref-aff" href="#aff-12">12</a>, </li><li class="contributor" id="contrib-13"><span class="name">Jiuyong Yang</span><span class="contrib-role">, chest physician</span><a id="xref-aff-13-1" class="xref-aff" href="#aff-13">13</a>, </li><li class="contributor" id="contrib-14"><span class="name">Jun Lin</span><span class="contrib-role">, gastrointestinal physician</span><a id="xref-aff-14-1" class="xref-aff" href="#aff-14">14</a>, </li><li class="contributor" id="contrib-15"><span class="name">Qingxia Zhao</span><span class="contrib-role">, infectious diseases physician</span><a id="xref-aff-15-1" class="xref-aff" href="#aff-15">15</a>, </li><li class="contributor" id="contrib-16"><span class="name">Youqin Yan</span><span class="contrib-role">, infectious diseases physician</span><a id="xref-aff-16-1" class="xref-aff" href="#aff-16">16</a>, </li><li class="contributor" id="contrib-17"><span class="name">Zhibin Xie</span><span class="contrib-role">, chest physician</span><a id="xref-aff-17-1" class="xref-aff" href="#aff-17">17</a>, </li><li class="contributor" id="contrib-18"><span class="name">Dan Li</span><span class="contrib-role">, chest physician</span><a id="xref-aff-18-1" class="xref-aff" href="#aff-18">18</a>, </li><li class="contributor" id="contrib-19"><span class="name">Yaofeng Yang</span><span class="contrib-role">, chest physician</span><a id="xref-aff-19-1" class="xref-aff" href="#aff-19">19</a>, </li><li class="contributor" id="contrib-20"><span class="name">Leshan Liu</span><span class="contrib-role">, associate research fellow in statistics</span><a id="xref-aff-20-1" class="xref-aff" href="#aff-20">20</a>, </li><li class="contributor" id="contrib-21"><span class="name">Jieming Qu</span><span class="contrib-role">, chest physician and professor</span><a id="xref-aff-1-3" class="xref-aff" href="#aff-1">1 </a><a id="xref-aff-2-3" class="xref-aff" href="#aff-2">2</a>, </li><li class="contributor" id="contrib-22"><span class="name">Guang Ning</span><span class="contrib-role">, endocrinology physician and professor</span><a id="xref-aff-21-1" class="xref-aff" href="#aff-21">21</a>, </li><li class="contributor" id="contrib-23"><span class="name">Guochao Shi</span><span class="contrib-role">, chest physician and professor</span><a id="xref-aff-1-4" class="xref-aff" href="#aff-1">1 </a><a id="xref-aff-2-4" class="xref-aff" href="#aff-2">2</a>, </li><li class="last" id="contrib-24"><span class="name">Qing Xie</span><span class="contrib-role">, professor</span><a id="xref-aff-3-2" class="xref-aff" href="#aff-3">3</a></li></ol><ol class="affiliation-list"><li class="aff"><a id="aff-1" name="aff-1"></a><address><sup>1</sup>Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China</address></li><li class="aff"><a id="aff-2" name="aff-2"></a><address><sup>2</sup>Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China</address></li><li class="aff"><a id="aff-3" name="aff-3"></a><address><sup>3</sup>Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China</address></li><li class="aff"><a id="aff-4" name="aff-4"></a><address><sup>4</sup>Department of Respiratory Medicine, No 2 People’s Hospital of Fuyang City, Fuyang, Anhui, China</address></li><li class="aff"><a id="aff-5" name="aff-5"></a><address><sup>5</sup>Department of Respiratory Medicine, Suizhou Hospital, Hubei University of Medicine, Suizhou, Hubei, China</address></li><li class="aff"><a id="aff-6" name="aff-6"></a><address><sup>6</sup>Department of Respiratory and Critical Care Medicine, Xiangyang No 1 People’s Hospital, Hubei University of Medicine, Xiangyang, Hubei, China</address></li><li class="aff"><a id="aff-7" name="aff-7"></a><address><sup>7</sup>Department of Infectious Diseases, Central Hospital of Ezhou, Ezhou, Hubei, China</address></li><li class="aff"><a id="aff-8" name="aff-8"></a><address><sup>8</sup>Department of Cardiovascular Medicine, Yunmeng People’s Hospital, Xiaogan, Hubei, China</address></li><li class="aff"><a id="aff-9" name="aff-9"></a><address><sup>9</sup>Department of Respiratory Medicine, First People’s Hospital of Jingzhou City, Jingzhou, Hubei, China</address></li><li class="aff"><a id="aff-10" name="aff-10"></a><address><sup>10</sup>Department of Infectious Diseases, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei, China</address></li><li class="aff"><a id="aff-11" name="aff-11"></a><address><sup>11</sup>Department of Emergency Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China</address></li><li class="aff"><a id="aff-12" name="aff-12"></a><address><sup>12</sup>Department of Respiratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China</address></li><li class="aff"><a id="aff-13" name="aff-13"></a><address><sup>13</sup>Department of Respiratory Medicine, Hubei Space Hospital of Xiaogan, Xiaogan, Hubei, China</address></li><li class="aff"><a id="aff-14" name="aff-14"></a><address><sup>14</sup>Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China</address></li><li class="aff"><a id="aff-15" name="aff-15"></a><address><sup>15</sup>Department of Infectious Disease, The Sixth People’s Hospital of Zhengzhou, Zhengzhou, Henan, China</address></li><li class="aff"><a id="aff-16" name="aff-16"></a><address><sup>16</sup>Department of Infectious Disease, Wuhan No 7 Hospital, Wuhan, Hubei, China</address></li><li class="aff"><a id="aff-17" name="aff-17"></a><address><sup>17</sup>Departments of Respiratory Medicine, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei, China</address></li><li class="aff"><a id="aff-18" name="aff-18"></a><address><sup>18</sup>Department of Respiratory Medicine, The Third People’s Hospital of Yichang, Yichang, Hubei, China</address></li><li class="aff"><a id="aff-19" name="aff-19"></a><address><sup>19</sup>Department of Respiratory Medicine, Xiao Gan First People’s Hospital, Xiaogan, Hubei Province, China</address></li><li class="aff"><a id="aff-20" name="aff-20"></a><address><sup>20</sup>Clinical Research Centre, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China</address></li><li class="aff"><a id="aff-21" name="aff-21"></a><address><sup>21</sup>Shanghai National Research Centre for Endocrine and Metabolic Diseases, State Key Laboratory of Medical Genomics, Shanghai Institute for Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China</address></li></ol><ol class="corresp-list"><li class="corresp" id="corresp-1">Correspondence to: Q Xie <span class="em-link"><span class="em-addr">xieqingrjh{at}163.com</span></span></li></ol><ul class="history-list"><li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted" hwp:start="2020-05-06"><span class="accepted-label">Accepted </span>6 May 2020</li></ul></div><div class="section abstract" id="abstract-1"><h2 class="">Abstract</h2><div id="sec-1" class="subsection"><p id="p-2"><strong>Objective</strong> To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).</p></div><div id="sec-2" class="subsection"><p id="p-3"><strong>Design</strong> Multicentre, open label, randomised controlled trial.</p></div><div id="sec-3" class="subsection"><p id="p-4"><strong>Setting</strong> 16 government designated covid-19 treatment centres in China, 11 to 29 February 2020.</p></div><div id="sec-4" class="subsection"><p id="p-5"><strong>Participants</strong> 150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone).</p></div><div id="sec-5" class="subsection"><p id="p-6"><strong>Interventions</strong> Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively).</p></div><div id="sec-6" class="subsection"><p id="p-7"><strong>Main outcome measure</strong> Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according to the intention to treat principle. Adverse events were analysed in the safety population in which hydroxychloroquine recipients were participants who received at least one dose of hydroxychloroquine and hydroxychloroquine non-recipients were those managed with standard of care alone.</p></div><div id="sec-7" class="subsection"><p id="p-8"><strong>Results</strong> Of 150 patients, 148 had mild to moderate disease and two had severe disease. The mean duration from symptom onset to randomisation was 16.6 (SD 10.5; range 3-41) days. A total of 109 (73%) patients (56 standard of care; 53 standard of care plus hydroxychloroquine) had negative conversion well before 28 days, and the remaining 41 (27%) patients (19 standard of care; 22 standard of care plus hydroxychloroquine) were censored as they did not reach negative conversion of virus. The probability of negative conversion by 28 days in the standard of care plus hydroxychloroquine group was 85.4% (95% confidence interval 73.8% to 93.8%), similar to that in the standard of care group (81.3%, 71.2% to 89.6%). The difference between groups was 4.1% (95% confidence interval –10.3% to 18.5%). In the safety population, adverse events were recorded in 7/80 (9%) hydroxychloroquine non-recipients and in 21/70 (30%) hydroxychloroquine recipients. The most common adverse event in the hydroxychloroquine recipients was diarrhoea, reported in 7/70 (10%) patients. Two hydroxychloroquine recipients reported serious adverse events.</p></div><div id="sec-8" class="subsection"><p id="p-9"><strong>Conclusions</strong> Administration of hydroxychloroquine did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate covid-19. Adverse events were higher in hydroxychloroquine recipients than in non-recipients.</p></div><div id="sec-9" class="subsection"><p id="p-10"><strong>Trial registration</strong> ChiCTR2000029868.</p></div></div><div class="section intro" id="sec-10"><h2 class="">Introduction</h2><p id="p-11">Coronavirus disease 2019 (covid-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread to most countries in the world within five months of initial reports in China. As of 22 April 2020, more than 2.5 million infections and 178 thousand deaths had been reported.<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a></p><p id="p-12">Several drugs, including remdesivir, favipiravir, ribavirin, lopinavir-ritonavir (used in combination), and chloroquine or hydroxychloroquine, have been highlighted on the basis of promising in vitro results and therapeutic experiences from two other coronavirus diseases—severe acute respiratory syndrome and Middle East respiratory syndrome.<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a> However, none of these promising results has yet been translated into clinical benefits in patients with covid-19, with a failed trial of lopinavir-ritonavir being the most recently reported.<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a></p><p id="p-13">Chloroquine and its hydroxyl analogue hydroxychloroquine, best known as antimalarial drugs, are prominent on the list of potential covid-19 treatments, owing to potent antiviral activity against SARS-CoV-2 in the in vitro studies and news reports of promising results from some ongoing trials.<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a><a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a><a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a> Despite their unclear benefits, chloroquine and hydroxychloroquine are both recommended for off label use in the treatment of covid-19 by the Chinese national guideline,<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a> and the US Food and Drug Administration recently authorised them for emergency use.<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a> US president Donald Trump also recently recommended use of hydroxychloroquine. Such a presidential endorsement stimulated an rapid increase in demand for hydroxychloroquine, which obscured the negative aspects of this drug. Deaths due to chloroquine overdoses have been reported in Nigeria among people self-treating for apparent covid-19.<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a> Retinopathy and gastrointestinal and cardiac side effects are well documented with the use of chloroquine or hydroxychloroquine in the treatment of malarial and rheumatic diseases.<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a> Hydroxychloroquine is preferred in clinical applications owing to its lower toxicity, particularly retinal toxicity,<a id="xref-ref-10-2" class="xref-bibr" href="#ref-10">10</a> and three times the potency against SARS-CoV-2 infection compared with chloroquine in a recent in vitro study.<a id="xref-ref-5-2" class="xref-bibr" href="#ref-5">5</a> No convincing evidence from well designed clinical trials exists to support the use of chloroquine or hydroxychloroquine with good efficacy and safety for the treatment of covid-19. Rapidly conducting such trials with high quality is challenging in the face of a dangerous coronavirus outbreak, in which healthcare workers have an overwhelming amount of work and the highest risk of developing covid-19.<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a></p><p id="p-14">Having encountered many challenges, we conducted a multicentre, open label, randomised controlled trial to assess the efficacy and safety of hydroxychloroquine sulfate in adult patients with covid-19.</p></div><div class="section methods" id="sec-11"><h2 class="">Methods</h2><div id="sec-12" class="subsection"><h3>Trial oversight</h3><p id="p-15">The principal investigators (QX, GS, GN, and JQ) designed and initiated the study after approval of the protocol by the institutional review board in Ruijin Hospital on 6 February 2020. The protocol and approval documents are available in the online supplement. All patients gave written informed consent. The principal investigators invited hospitals with the capability to provide the current standard of care for covid-19 to participate in the study. Minimum requirements for the standard of care included the provision of intravenous fluids, supplemental oxygen, regular laboratory testing, SARS-CoV-2 testing, haemodynamic monitoring, and intensive care, as well as the ability to deliver concomitant medications. The trial was conducted urgently during the outbreak of covid-19 in compliance with the Declaration of Helsinki, Good Clinical Practice guidelines, and local regulatory requirements. Shanghai Pharmaceuticals Holding donated the investigated drug, hydroxychloroquine but was not involved in the study design, accrual, analyses of data, or preparation of the manuscript. A contract research organisation, R&amp;G PharmaStudies, was hired to assist in the study design, data collection and cleaning, and statistical analyses. Data were recorded by clinical research coordinators, followed by queries from clinical research associates. The study statistician then entered confirmed data into the OpenClinica database for statistical analyses performed by and reviewed by the senior statistician in accordance with Good Clinical Practice guidelines. Data collection forms and statistical analysis plans are available in the online supplement.</p><p id="p-16">An independent data and safety monitoring committee (IDMC) periodically reviewed the progress and oversight of the study. The interim analysis took place on 14 March, and the results were presented to the IDMC. The rapid decline in eligible new cases of covid-19 in China at that time precluded recruitment of our targeted number of patients. After a two round extensive review of the efficacy and safety data generated from the interim analysis, the IDMC endorsed an early termination of the trial. Members of the committee all agreed that the data from the trial are important for clinicians, the public, and the government to avoid inappropriate use of hydroxychloroquine in the clinical management of covid-19, particularly in areas with overwhelming patient numbers. The report of the trial could be an important resource to facilitate better design of future trials. The results of this clinical trial are reported in accordance with CONSORT (Consolidated Standards of Reporting Trials) guidelines.</p></div><div id="sec-13" class="subsection"><h3>Trial design, randomisation, and procedures</h3><p id="p-17">This study was a multicentre, randomised, parallel, open label trial of hydroxychloroquine in patients admitted to hospital with covid-19. Patients were enrolled by the site investigators in 16 government designated covid-19 treatment centres in three provinces in China (Hubei, Henan, and Anhui). No placebo was used, and drugs were not masked. We applied stratified random sampling to stratify all eligible patients according to disease severity (mild/moderate or severe), followed by random assignment (in a 1:1 ratio) in each stratum to ensure a balanced distribution of disease severity between treatment (hydroxychloroquine plus standard of care) and control (standard of care only) groups. LL designed the randomisation rules together with the principal investigators, and an independent statistician who was not involved in data analysis implemented them. Equal numbers of cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled. All patients were managed with standard of care aligned with the indications from the updated national clinical practice guidelines for covid-19 in China. Patients in the treatment group were given hydroxychloroquine within 24 hours after randomisation, with a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily for the remaining days (total treatment duration was two weeks for patients with mild to moderate disease and three weeks for those with severe disease). The dose of hydroxychloroquine was adjusted when adverse events were related to hydroxychloroquine, as judged by investigators. Details of dose adjustment are provided in the study protocol available in the online supplement. Patients, investigators, and statisticians were not masked to treatment assignment. Laboratory technicians who did virological, chemical, and other routine measurements were unaware of treatment information.</p></div><div id="sec-14" class="subsection"><h3>Patients</h3><p id="p-18">Inclusion criteria were age 18 years or older, ongoing SARS-CoV-2 infection confirmed in upper or lower respiratory tract specimens with real time reverse transcriptase polymerase chain reaction (RT-PCR), willingness to participate, and consent not to be enrolled in other clinical trials during the study period. Pneumonia on computed tomography of the chest was not mandatory for inclusion.</p><p id="p-19">Exclusion criteria were age below 18 years; severe conditions including malignancies, heart, liver, or kidney disease or poorly controlled metabolic diseases; unsuitability for oral administration; pregnancy or lactation; allergy to hydroxychloroquine; inability to cooperate with investigators due to cognitive impairments or poor mental status; severe hepatic impairment (for example, Child Pugh grade C, alanine aminotransferase more than fivefold the upper limit); and severe renal impairment (estimated glomerular filtration rate ≤30 mL/min/1.73 m<sup>2</sup>) or receipt of continuous renal replacement therapy, haemodialysis, or peritoneal dialysis. In the original protocol, patients with severe covid-19 were excluded. Considering that the anti-inflammatory property of hydroxychloroquine might favour disease regression, we decided to include patients with severe covid-19 (change approved by the ethics committee on 17 February 2020).</p><p id="p-20">The definition of disease severity of covid-19 was based on the fifth version of the Chinese guideline for the management of covid-19.<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a> Mild disease includes patients with mild symptoms but no manifestation of pneumonia on imaging. Moderate disease includes patients with fever, cough, sputum production, and other respiratory tract or non-specific symptoms along with manifestation of pneumonia on imaging but no signs of severe pneumonia defined as the presence of SaO<sub>2</sub>/SpO<sub>2</sub> below 94% on room air or a PaO<sub>2</sub> to FiO<sub>2</sub> ratio of 300 or lower.</p></div><div id="sec-15" class="subsection"><h3>Assessment</h3><p id="p-21">Specimens from the upper respiratory tract, lower respiratory tract, or both were obtained from each patient on screening (day –3 to day 1) and during treatment and post-treatment follow-up at scheduled visits on days 4, 7, 10, 14, 21, and 28. The local Centre for Disease Control and Prevention or authorised health institutions or hospitals at each site measured SARS-CoV-2 by using assays approved by the National Medical Products Administration. Measurements were performed according to the recommendations of the National Institute for Viral Disease Control and Prevention (China) (<a href="http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html">http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html</a>). Methods for extraction and amplification of total RNA through RT-PCR were similar to those described elsewhere.<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a> Rather than quantitative data (cycle threshold value) reported from the RT-PCR assay, we collected only qualitative data reported from our trial sites. On the basis of a national recommendation, we defined a cycle threshold value less than 37 as a positive test result and a cycle threshold value of 40 or more as a negative test. Cycle threshold values between 37 and 40 confirmed by retesting were reported as unclassified.</p><p id="p-22">In addition to SARS-CoV-2 testing, patients were assessed on each scheduled visit for vital signs, C reactive protein, erythrocyte sedimentation rate, tumour necrosis factor α, interleukin 6, complete blood cell count with differential, blood chemistry, coagulation panel, pulse oximetry, and respiratory symptoms. Records of administration of hydroxychloroquine and adverse events were reviewed daily to ensure fidelity to the protocol and, more importantly, patient safety. Computed tomography of the chest was assessed on screening and at the last visit of the treatment period (day 14 for patients with mild to moderate disease and day 21 for severe disease). Computed tomography examinations of the chest could be exempted by the investigators if the participants could provide qualified examination results within three days before the start of the study. More details on data collection are provided in the protocol available in the supplement.</p></div><div id="sec-16" class="subsection"><h3>Outcome</h3><p id="p-23">The primary outcomes for this trial were whether patients had negative conversion of SARS-CoV-2 by 28 days and whether patients with severe covid-19 had clinical improvement by 28 days. However, as the trial was stopped early and only two patients with severe disease were enrolled, results on clinical improvement are not presented. We defined negative conversion of SARS-CoV-2 as two consecutive reports of a negative result for SARS-CoV-2 at least 24 hours apart without a subsequent report of a positive result by the end of the study. We considered the date of the first negative report as the date of negative conversion. In the original protocol, the primary endpoint was prespecified as the “Negative conversion rate by Day 10” (approved by the ethics committee on 6 February 2020). However, with the increasing knowledge of covid-19 from our clinical practice, we realised that the duration of SARS-CoV-2 in respiratory samples of many patients was longer than 10 days, recently highlighted by a detailed virological study.<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a> We therefore modified our primary outcome to test whether patients had a negative conversion of SARS-CoV-2 by 28 days (approved by the ethics committee on 17 February 2020). Probability of negative conversion at day 4, 7, 10, 14, or 21 was specified as a secondary outcome in the protocol, but this does not appear on the trial registration list. The listed secondary outcome in the trial registration was adverse events coded using the latest version of Medical Dictionary for Regulatory Activities coding dictionary, recorded in standard medical terminology and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events.</p><p id="p-24">Other prespecified secondary outcomes not listed in the trial registration but included in the protocol were the probabilities of alleviation of clinical symptoms; improvement of C reactive protein, erythrocyte sedimentation rate, tumour necrosis factor α, interleukin 6, and absolute blood lymphocyte count; improvement of lung lesions on chest radiology; all cause death; and disease progression in patients with mild to moderate disease. The time frame for these secondary outcomes was from randomisation to 28 days. Prespecified secondary outcomes for patients with severe disease are not listed here but are included in the protocol. Owing to the early termination of our study, we could not justify the results from these analyses with an underpowered sample size and therefore decided not to emphasise them in this paper to avoid misinterpretation. The only one presented here is the alleviation of clinical symptoms within 28 days, which is an important outcome of interest prespecified in our protocol. The definition of the alleviation of clinical symptoms was resolving from fever to an axillary temperature of 36.6°C or below, normalisation of SpO<sub>2</sub> (&gt;94% on room air), and disappearance of respiratory symptoms including nasal congestion, cough, sore throat, sputum production, and shortness of breath.</p></div><div id="sec-17" class="subsection"><h3>Statistical analysis</h3><p id="p-25">In the original protocol, the target number of enrolments was set to 200 without type I error control. In the updated protocol (approved by the ethics committee on 10 February 2020), we considered type I and type II error control and recalculated the sample size. The sample size was calculated on the basis of the alternative hypothesis of a 30% increase in the rate of conversion to negative for SARS-CoV-2 as defined by virus nucleic acid negativity. With the assumption that time to conversion follows an exponential distribution, if the median time to conversion with hydroxychloroquine can be reduced from 10 days to seven days, a total of 248 events would provide a power of 80% to detect a hazard ratio of 0.7 (standard of care <em>v</em> hydroxychloroquine) with a log rank test. Additionally, we assumed a 75 day accrual period and a seven day follow-up after enrolment of the last patient, so about 360 patients (180 per group) would be randomised in the study. An interim analysis was planned when around 150 patients were treated for at least seven days. We applied the O’Brien-Fleming cumulative α spending function by Lan-DeMets algorithm to control for family-wise type I error=0.05.</p><p id="p-26">We estimated the overall probability of negative conversion by analysing time to negative conversion of SARS-CoV-2 using the Kaplan-Meier method in the intention to treat population and compared groups with a log rank test. We considered patients who did not reach the negative conversion of SARS-CoV-2 (see definition in Outcome section) by the cut-off date of the analysis (14 March 2020) to be right censored at the last visit date. All these patients remained in hospital and may have reached negative conversion after our last visit date, but the specific timing of the event is unknown. We applied similar approaches to the analysis of alleviation of symptoms. We used the rate difference between groups to show the treatment effect size and estimated 95% confidence intervals by an approximate normal distribution and the standard error by the bootstrap method (n=1000). We used a Cox model to estimate the hazard ratio. Hazard ratios greater than one indicate that the rate of negative conversion of virus or alleviation of symptoms was higher in the hydroxychloroquine plus standard of care group than in the standard of care only group. Safety analyses were based on the patients’ actual exposure to treatment. We used SAS version 9.4 for data analyses.</p></div><div id="sec-18" class="subsection"><h3>Patient and public involvement</h3><p id="p-27">No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for recruitment, design, or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.</p></div></div><div class="section results" id="sec-19"><h2 class="">Results</h2><div id="sec-20" class="subsection"><h3>Patients</h3><p id="p-28">Of 191 patients admitted to hospital with covid-19 from 11 to 29 February 2020, 41 did not meet the eligibility criteria. The remaining 150 patients were randomised: 75 patients were assigned to standard of care and 75 patients to standard of care plus hydroxychloroquine (<a id="xref-fig-1-1" class="xref-fig" href="#F1">fig 1</a>). The mean age of the patients was 46 years, and 82 (55%) were male. The mean duration from onset of symptoms to randomisation was 16.6 (SD 10.5; range 3-41) days, and 90 (60%) patients received concomitant drug treatment before randomisation. Among these, 52 (35%) patients received antiviral treatment (<a id="xref-table-wrap-1-1" class="xref-table" href="#T1">table 1</a>). Almost all (148; 99%) patients had mild to moderate covid-19, and only 2 (1%) patients had severe disease on screening. <a id="xref-table-wrap-1-2" class="xref-table" href="#T1">Table 1</a> shows baseline demographic, epidemiological, and clinical characteristics of the patients in the two groups.</p><div id="F1" class="fig pos-float type-figure  odd"><div class="fig-inline"><div class="highwire-figure"><div class="fig-inline-img-wrapper"><div class="fig-inline-img"><a href="https://www.bmj.com/content/bmj/369/bmj.m1849/F1.large.jpg?width=800&amp;height=600" title="Screening, randomisation, and follow-up of trial participants" class="colorbox fragment-images colorbox-load" rel="gallery-fragment-images" data-figure-caption="&lt;div class=&quot;highwire-markup&quot;&gt;&lt;div class=&quot;fig-caption&quot; xmlns:xhtml=&quot;http://www.w3.org/1999/xhtml&quot;&gt;&lt;span class=&quot;fig-label&quot;&gt;Fig 1&lt;/span&gt; &lt;p id=&quot;p-29&quot; class=&quot;first-child&quot;&gt;Screening, randomisation, and follow-up of trial participants&lt;/p&gt;&lt;div class=&quot;sb-div caption-clear&quot;&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;"><img class="fragment-image" src="https://www.bmj.com/content/bmj/369/bmj.m1849/F1.medium.jpg" alt="Fig 1"/></a></div></div><div xmlns:xhtml="http://www.w3.org/1999/xhtml" class="fig-caption"><span class="fig-label">Fig 1</span> <p id="p-29" class="first-child">Screening, randomisation, and follow-up of trial participants</p><div class="sb-div caption-clear"></div></div><ul class="highwire-figure-links list-inline"><li class="download-fig first"><a href="https://www.bmj.com/content/bmj/369/bmj.m1849/F1.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig 1">Download figure</a></li>
<li class="new-tab"><a href="https://www.bmj.com/content/bmj/369/bmj.m1849/F1.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank">Open in new tab</a></li>
<li class="download-ppt last"><a href="/highwire/powerpoint/1027158" class="highwire-figure-link highwire-figure-link-ppt">Download powerpoint</a></li>
</ul></div></div><div class="fig-caption" xmlns:xhtml="http://www.w3.org/1999/xhtml"></div></div><div id="T1" class="table pos-float"><div class="table"><div class="table-caption"><span class="table-label">Table 1</span> <p id="p-30" class="first-child">Baseline demographic and clinical characteristics of patients in intention to treat population. Values are numbers (percentages) unless stated otherwise</p><div class="sb-div caption-clear"></div></div><div class="table-inline"><div class="callout"><span>View this table:</span><ul class="callout-links"><li><a href="/highwire/markup/1027160/expansion?width=1000&amp;height=500&amp;iframe=true&amp;postprocessors=highwire_figures%2Chighwire_math" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables">View popup</a></li><li><a href="" class="table-expand-inline" data-table-url="/highwire/markup/1027160/expansion?postprocessors=highwire_figures%2Chighwire_math">View inline</a></li></ul></div></div></div><div></div></div><p id="p-34">By 14 March 2020 (the cut-off date for data analysis), the median duration of follow-up was 21 (range 2-33) days in the standard of care group and 20 (3-31) days in the standard of care plus hydroxychloroquine group; nine patients in each group had completed 28 days of follow-up. Of the 75 patients assigned to receive standard of care plus hydroxychloroquine, six patients did not receive any dose of hydroxychloroquine (three withdrew consent and three refused to be treated with hydroxychloroquine). Concomitant treatments, including antiviral agents, antibiotics, and systemic glucocorticoid therapy, were similar in the two groups (<a id="xref-table-wrap-2-1" class="xref-table" href="#T2">table 2</a>). One patient with moderate disease in the hydroxychloroquine group progressed to severe covid-19, and no patients died during follow-up.</p><div id="T2" class="table pos-float"><div class="table"><div class="table-caption"><span class="table-label">Table 2</span> <p id="p-35" class="first-child">Treatments after randomisation in patients in intention to treat population. Values are numbers (percentages)</p><div class="sb-div caption-clear"></div></div><div class="table-inline"><div class="callout"><span>View this table:</span><ul class="callout-links"><li><a href="/highwire/markup/1027157/expansion?width=1000&amp;height=500&amp;iframe=true&amp;postprocessors=highwire_figures%2Chighwire_math" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables">View popup</a></li><li><a href="" class="table-expand-inline" data-table-url="/highwire/markup/1027157/expansion?postprocessors=highwire_figures%2Chighwire_math">View inline</a></li></ul></div></div></div><div></div></div></div><div id="sec-21" class="subsection"><h3>Primary outcome</h3><p id="p-37">A total of 109 (73%) patients (56 standard of care; 53 standard of care plus hydroxychloroquine) had negative conversion well before 28 days, and the remaining 41 (27%) patients (19 standard of care; 22 standard of care plus hydroxychloroquine) were censored as they did not reach negative conversion of virus. The maximum duration for a patient with positive SARS-CoV-2 was 23 days by the cut-off date of our analysis. Overall, the probability of negative conversion of SARS-CoV-2 among patients who were assigned to receive standard of care plus hydroxychloroquine was 85.4% (95% confidence interval 73.8% to 93.8%) by 28 days, similar to that of the standard of care group (81.3%, 71.2% to 89.6%). The difference in the probability of negative conversion between standard of care plus hydroxychloroquine and standard of care alone was 4.1% (95% confidence interval –10.3% to 18.5%). The median time to negative conversion was also similar in the standard of care plus hydroxychloroquine group (8 (95% confidence interval 5 to 10) days) to that in the standard of care group (7 (5 to 8) days) (hazard ratio 0.85, 95% confidence interval 0.58 to 1.23; P=0.34 by log rank test; <a id="xref-fig-2-1" class="xref-fig" href="#F2">fig 2</a>).</p><div id="F2" class="fig pos-float type-figure  odd"><div class="fig-inline"><div class="highwire-figure"><div class="fig-inline-img-wrapper"><div class="fig-inline-img"><a href="https://www.bmj.com/content/bmj/369/bmj.m1849/F2.large.jpg?width=800&amp;height=600" title="Kaplan-Meier curves of time to negative conversion of SARS-CoV-2 on real time reverse transcription polymerase chain reaction (RT-PCR) test in standard of care (SOC) plus hydroxychloroquine (HCQ) versus SOC in intention to treat population. Data are shown for 75 patients assigned to SOC plus HCQ and 75 assigned to SOC. Overall probability of negative conversion by 28 days was 85.4% (95% CI 73.8% to 93.8%) in SOC plus HCQ group and 81.3% (71.2% to 89.6%) in SOC group (P=0.34). Difference between groups was 4.1% (95% CI &#x2013;10.3% to 18.5%). Median time to negative conversion was 8 (95% CI 5 to 10) days in SOC plus HCQ group and 7 (5 to 8) days SOC group (hazard ratio 0.85, 95% CI 0.58 to 1.23; P=0.34 by log rank test). Data from patients who did not have negative conversion were censored (tick marks) at last visit date" class="colorbox fragment-images colorbox-load" rel="gallery-fragment-images" data-figure-caption="&lt;div class=&quot;highwire-markup&quot;&gt;&lt;div class=&quot;fig-caption&quot; xmlns:xhtml=&quot;http://www.w3.org/1999/xhtml&quot;&gt;&lt;/div&gt;&lt;/div&gt;"><img class="fragment-image" src="https://www.bmj.com/content/bmj/369/bmj.m1849/F2.medium.jpg" alt="Fig 2"/></a></div></div><div xmlns:xhtml="http://www.w3.org/1999/xhtml" class="fig-caption"><span class="fig-label">Fig 2</span> <p id="p-38" class="first-child">Kaplan-Meier curves of time to negative conversion of SARS-CoV-2 on real time reverse transcription polymerase chain reaction (RT-PCR) test in standard of care (SOC) plus hydroxychloroquine (HCQ) versus SOC in intention to treat population. Data are shown for 75 patients assigned to SOC plus HCQ and 75 assigned to SOC. Overall probability of negative conversion by 28 days was 85.4% (95% CI 73.8% to 93.8%) in SOC plus HCQ group and 81.3% (71.2% to 89.6%) in SOC group (P=0.34). Difference between groups was 4.1% (95% CI –10.3% to 18.5%). Median time to negative conversion was 8 (95% CI 5 to 10) days in SOC plus HCQ group and 7 (5 to 8) days SOC group (hazard ratio 0.85, 95% CI 0.58 to 1.23; P=0.34 by log rank test). Data from patients who did not have negative conversion were censored (tick marks) at last visit date</p><div class="sb-div caption-clear"></div></div><ul class="highwire-figure-links list-inline"><li class="download-fig first"><a href="https://www.bmj.com/content/bmj/369/bmj.m1849/F2.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig 2">Download figure</a></li>
<li class="new-tab"><a href="https://www.bmj.com/content/bmj/369/bmj.m1849/F2.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank">Open in new tab</a></li>
<li class="download-ppt last"><a href="/highwire/powerpoint/1027159" class="highwire-figure-link highwire-figure-link-ppt">Download powerpoint</a></li>
</ul></div></div><div class="fig-caption" xmlns:xhtml="http://www.w3.org/1999/xhtml"></div></div></div><div id="sec-22" class="subsection"><h3>Safety</h3><p id="p-39">Six patients who were assigned to the standard of care plus hydroxychloroquine group but did not receive hydroxychloroquine treatment were classified as hydroxychloroquine non-recipients in the safety population. One patient in the standard of care group wrongly received 14 days of hydroxychloroquine treatment with an accumulative dose of 11 600 mg. This patient was classified as a hydroxychloroquine recipient in the safety population (<a id="xref-fig-1-2" class="xref-fig" href="#F1">fig 1</a>). We compared safety endpoints between hydroxychloroquine recipients and non-recipients (<a id="xref-table-wrap-3-1" class="xref-table" href="#T3">table 3</a>). In hydroxychloroquine recipients, the median duration of hydroxychloroquine treatment was 14 (range 1-22) days. Between randomisation and the final visit, 21 (30%) patients in the standard of care plus hydroxychloroquine group reported adverse events, compared with 7 (9%) patients in the standard of care group (<a id="xref-table-wrap-3-2" class="xref-table" href="#T3">table 3</a>). No serious adverse events were reported in the standard of care group. Two patients in the hydroxychloroquine group reported serious adverse events due to disease progression and upper respiratory infection. The patient with upper respiratory infection was discharged after finishing the 14 days of treatment with hydroxychloroquine and developed throat drying and pharyngalgia requiring readmission without evidence of pneumonia on computed tomography of the chest during the extended follow-up period.</p><div id="T3" class="table pos-float"><div class="table"><div class="table-caption"><span class="table-label">Table 3</span> <p id="p-40" class="first-child">Summary of adverse events in safety population. Values are numbers (percentages)</p><div class="sb-div caption-clear"></div></div><div class="table-inline"><div class="callout"><span>View this table:</span><ul class="callout-links"><li><a href="/highwire/markup/1027156/expansion?width=1000&amp;height=500&amp;iframe=true&amp;postprocessors=highwire_figures%2Chighwire_math" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables">View popup</a></li><li><a href="" class="table-expand-inline" data-table-url="/highwire/markup/1027156/expansion?postprocessors=highwire_figures%2Chighwire_math">View inline</a></li></ul></div></div></div><div></div></div><p id="p-43">The most common adverse event in the standard of care plus hydroxychloroquine group was diarrhoea, reported in 7 (10%) patients, which was not reported in the standard of care group. Hydroxychloroquine was discontinued in one patient owing to blurred vision and was adjusted to give a lower dose in one patient who reported thirst. These two adverse events were both transient with a duration of one to two days.</p></div><div id="sec-23" class="subsection"><h3>Secondary outcome</h3><p id="p-44">Probability of negative conversion by a specific time point—4, 7, 10, 14, or 21 days—was also similar in the two groups (supplementary table A). The probability of alleviation of symptoms by 28 days was similar in patients with standard of care with hydroxychloroquine (59.9%, 95% confidence interval 45.0% to 75.3%) and without hydroxychloroquine (66.6%, 39.5% to 90.9%). The difference between groups was –6.6% (–41.3% to 28.0%). The median time to alleviation of clinical symptoms was similar in the standard of care plus hydroxychloroquine group to that in the standard of care group (19 <em>v</em> 21 days; hazard ratio 1.01, 0.59 to 1.74; P=0.97 by log rank test; <a id="xref-fig-3-1" class="xref-fig" href="#F3">fig 3</a>).</p><div id="F3" class="fig pos-float type-figure  odd"><div class="fig-inline"><div class="highwire-figure"><div class="fig-inline-img-wrapper"><div class="fig-inline-img"><a href="https://www.bmj.com/content/bmj/369/bmj.m1849/F3.large.jpg?width=800&amp;height=600" title="Kaplan-Meier curves of time to alleviation of clinical symptoms with standard of care (SOC) plus hydroxychloroquine (HCQ) versus SOC alone in intention to treat population. Data shown are for 55 patients with symptoms assigned to SOC plus HCQ and 64 assigned to SOC. Probability of alleviation of symptoms by 28 days was similar (P=0.97) in patients with SOC with (59.9%, 95% confidence interval 45.0% to 75.3%) and without HCQ (66.6%, 39.5% to 90.9%). Difference between groups was &#x2013;6.6% (95% CI &#x2013;41.3% to 28.0%). Median time to alleviation of clinical symptoms was similar in SOC plus HCQ group and SOC group (19 v 21 days; hazard ratio 1.01, 95% confidence interval 0.59 to 1.74; P=0.97 by log rank test). Data from patients who did not have alleviation of symptoms were censored (tick marks) at last visit date" class="colorbox fragment-images colorbox-load" rel="gallery-fragment-images" data-figure-caption="&lt;div class=&quot;highwire-markup&quot;&gt;&lt;div class=&quot;fig-caption&quot; xmlns:xhtml=&quot;http://www.w3.org/1999/xhtml&quot;&gt;&lt;/div&gt;&lt;/div&gt;"><img class="fragment-image" src="https://www.bmj.com/content/bmj/369/bmj.m1849/F3.medium.jpg" alt="Fig 3"/></a></div></div><div xmlns:xhtml="http://www.w3.org/1999/xhtml" class="fig-caption"><span class="fig-label">Fig 3</span> <p id="p-45" class="first-child">Kaplan-Meier curves of time to alleviation of clinical symptoms with standard of care (SOC) plus hydroxychloroquine (HCQ) versus SOC alone in intention to treat population. Data shown are for 55 patients with symptoms assigned to SOC plus HCQ and 64 assigned to SOC. Probability of alleviation of symptoms by 28 days was similar (P=0.97) in patients with SOC with (59.9%, 95% confidence interval 45.0% to 75.3%) and without HCQ (66.6%, 39.5% to 90.9%). Difference between groups was –6.6% (95% CI –41.3% to 28.0%). Median time to alleviation of clinical symptoms was similar in SOC plus HCQ group and SOC group (19 <em>v</em> 21 days; hazard ratio 1.01, 95% confidence interval 0.59 to 1.74; P=0.97 by log rank test). Data from patients who did not have alleviation of symptoms were censored (tick marks) at last visit date</p><div class="sb-div caption-clear"></div></div><ul class="highwire-figure-links list-inline"><li class="download-fig first"><a href="https://www.bmj.com/content/bmj/369/bmj.m1849/F3.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig 3">Download figure</a></li>
<li class="new-tab"><a href="https://www.bmj.com/content/bmj/369/bmj.m1849/F3.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank">Open in new tab</a></li>
<li class="download-ppt last"><a href="/highwire/powerpoint/1027161" class="highwire-figure-link highwire-figure-link-ppt">Download powerpoint</a></li>
</ul></div></div><div class="fig-caption" xmlns:xhtml="http://www.w3.org/1999/xhtml"></div></div></div></div><div class="section discussion" id="sec-24"><h2 class="">Discussion</h2><p id="p-46">This study (conducted during the outbreak of covid-19 in China) is the first randomised controlled trial evaluating administration of hydroxychloroquine in patients with covid-19. The findings do not provide evidence to support an increase in the probability of negative conversion of SARS-CoV-2 conferred by the addition of hydroxychloroquine administration to the current standard of care in patients admitted to hospital with mainly persistent mild to moderate covid-19.</p><div id="sec-25" class="subsection"><h3>Comparison with other studies</h3><p id="p-47">The negative results on the antiviral efficacy of hydroxychloroquine obtained in this trial are contradictory to the encouraging in vitro results and the recently reported promising results from a non-randomised trial in 36 patients with covid-19.<a id="xref-ref-4-2" class="xref-bibr" href="#ref-4">4</a><a id="xref-ref-5-3" class="xref-bibr" href="#ref-5">5</a><a id="xref-ref-6-2" class="xref-bibr" href="#ref-6">6</a> Participants in our trial had mainly mild to moderate disease, with a median 16 day delay between symptom onset and hydroxychloroquine treatment, so the negative results of our trial are applicable only to patients with persistently mild to moderate covid-19. Covid-19 has overwhelmed hospital systems during the pandemic, and many of these patients may be treated in the community and may finally be admitted to hospital because of a need for oxygen or owing to rapid deterioration of the disease. Data from our trial do not provide evidence to support the use of hydroxychloroquine in this population, particularly considering the increased adverse events (discussed below). Our trial could not assess the antiviral efficacy of hydroxychloroquine at an earlier stage, such as within 48 hours of onset of the illness, the golden window for antiviral treatment in influenza.<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a> However, conducting such a trial is challenging in patients admitted to hospital and will be easier in outpatient or community settings. The fact that antiviral treatment was not restricted in our trial should also be considered when interpreting our results. Seeing the antiviral effects of hydroxychloroquine when compared with a “pure” control arm would be more conclusive. In the early dangerous outbreak of covid-19 in China, however, setting a restriction on drugs that could be potentially useful was not ethical. Nevertheless, the use of antiviral drugs before and after randomisation was balanced between the hydroxychloroquine and standard of care groups and thus might have little effect on our primary endpoint. Moreover, use of a higher dose of hydroxychloroquine than was used in our trial is not likely to have additional antiviral effects, because the dosage of hydroxychloroquine that we chose achieves the 50% effective concentration (EC<sub>50</sub>) of hydroxychloroquine against SARS-CoV-2,<a id="xref-ref-5-4" class="xref-bibr" href="#ref-5">5</a> although we did not monitor the concentration of hydroxychloroquine in our study. Another important message from our trial is that the Kaplan-Meier curve crossed over with time, suggesting a potential for a non-constant hazard ratio of negative conversion conferred by exposure to hydroxychloroquine. Therefore, the hazard ratios presented in our trial should be interpreted as weighted results over time rather than as a definitive constant. We will investigate this in the future. Further trials might also need to combat this problem when using the Cox regression method. Taken together, future studies could take advantage of our results to design trials in a more selective population, at the earliest stage possible (&lt;48 hours from illness onset), and using more sensitive endpoints, such as viral load shedding.</p><p id="p-48">Hydroxychloroquine in our trial was given at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily for a total treatment duration of two weeks or three weeks for patients with mild to moderate or severe disease, respectively. Serious adverse events occurred in two patients, and both were reported in hydroxychloroquine recipients. The overall frequency of adverse events was significantly higher in hydroxychloroquine recipients than in non-recipients. Gastrointestinal events, particularly diarrhoea, were most commonly reported, as they were in another study using a high dose of hydroxychloroquine.<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a> Transient blurred vision was reported in one patient whose symptoms recovered two days after discontinuation of hydroxychloroquine. Early development of retinal damage with a daily dose of 800 to 1200 mg was detected using sensitive retinal screening tests.<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a> Therefore, the retinal damage could be underestimated in our trial. Events of cardiac arrhythmia, such as prolonged QT interval,<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a> were not observed in our trial, possibly because of the relatively mild to moderate disease of patients investigated or the short term period of follow-up. However, with increasing interest in the combined use of hydroxychloroquine and azithromycin worldwide, physicians should be cautious about the increased risk of prolongation of the QT interval and fatal ventricular arrhythmia with azithromycin and other antimicrobial agents.<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a><a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a> Drug-drug interaction should be taken into consideration when assessing safety and efficacy endpoints in future trials of hydroxychloroquine.<a id="xref-ref-10-3" class="xref-bibr" href="#ref-10">10</a> The effects of hydroxychloroquine in causing increased concentrations of digitoxin and metoprolol would be particularly relevant in patients with severe covid-19 and would therefore require close monitoring.<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a></p></div><div id="sec-26" class="subsection"><h3>Strengths and limitations of study</h3><p id="p-49">This study provides the first and timely evidence about the benefit-risk profile of hydroxychloroquine derived from a multicentre randomised controlled trial, which was started during the most challenging time of the covid-19 outbreak in China. In such a situation, our study has several limitations. Firstly, the open label, as opposed to double blind, design introduces the possibility of biased investigator determined assessments and unbalanced dosage adjustment. Urgent production of placebos mimicking hydroxychloroquine and the management of a multicentre, placebo controlled trial remain challenging during the pandemic. Secondly, the use of sequential envelopes is inferior to the interactive web response management system for randomisation. Thirdly, the setting of our trial among patients admitted to hospital precluded us from enrolling patients at the early stage of disease. In addition, we cannot provide evidence on the effect of hydroxychloroquine on disease progression or regression because 148/150 (99%) patients in our trial had mild to moderate disease.</p><p id="p-50">Fourthly, the results of our main prespecified outcomes are not entirely conclusive, being based on an underpowered sample size due to the lack of enough eligible patients to enrol. The recruitment of eligible patients was unexpectedly difficult, with many clinical trials launched in the same period in response to the urgent call by the national health authorities for the exploration of effective treatment against covid-19. The rapid decline in eligible new cases owing to the successful containment of covid-19 in the middle of March 2020 in China precluded further recruitment to reach our targeted sample size. The premature termination of our trial also led to increased censoring of data on our primary outcome. We therefore reanalysed the probability of negative conversion in the two groups by using follow-up data to 27 April 2020 (supplementary table B), and the results were consistent with our reported results.</p><p id="p-51">Fifthly, ensuring fidelity to the protocol by site investigators under highly challenging circumstances in the covid-19 treatment centres was difficult. Hiring a contract research organisation, as we did in our trial, can greatly support the conduct and oversight of trials. Sixthly, population quarantine of Wuhan and neighbouring cities, nationwide travel restrictions, and isolation of cases and contacts were also barriers to collecting and transferring data and paper files. Several prespecified secondary endpoints, including the changes on computed tomography of the chest, were therefore not finished by the cut-off date for analysis. Finally, the specimens collected in our trial for virus RNA determination were mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which could introduce false negative results.<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a> However, the prespecified definition for negative conversion of virus was two consecutive negative results at least 24 hours apart, which can reduce false negativity.</p></div><div id="sec-27" class="subsection"><h3>Conclusion and policy implications</h3><p id="p-52">The results of our trial did not show additional benefits of virus elimination from adding hydroxychloroquine to the current standard of care in patients with mainly persistent mild to moderate covid-19. Adverse events, particularly gastrointestinal events, were more frequently reported in patients receiving hydroxychloroquine, who were given a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily for the remaining days for a total treatment duration of two weeks in patients with mild to moderate disease and three weeks in those with severe disease. Overall, these data do not support the addition of hydroxychloroquine to the current standard of care in patients with persistent mild to moderate covid-19 for eliminating the virus. Our trial may provide initial evidence for the benefit-risk profile of hydroxychloroquine and serve as a resource to support further research.</p><div class="boxed-text" id="boxed-text-1"><div id="sec-28" class="subsection"><h4>What is already known on this topic</h4><ul class="list-simple " id="list-1"><li id="list-item-1"><p id="p-53">The pandemic of coronavirus disease 2019 (covid-19) imposes a substantial burden on individuals, communities, healthcare facilities, markets, and governments globally</p></li><li id="list-item-2"><p id="p-54">No specific treatment has been approved for covid-19, and no vaccine exists to prevent infection with SARS-CoV-2</p></li><li id="list-item-3"><p id="p-55">During the urgent pandemic, media headlines encourage the use of drugs without solid evidence but ignore the side effects of these drugs</p></li></ul></div><div id="sec-29" class="subsection"><h4>What this study adds</h4><ul class="list-simple " id="list-2"><li id="list-item-4"><p id="p-56">In this randomised clinical trial of patients with mainly persistent mild to moderate covid-19, exposure to hydroxychloroquine led to a similar probability of virus elimination to the current standard of care</p></li><li id="list-item-5"><p id="p-57">Adverse events, mostly gastrointestinal, were significantly higher in patients who received hydroxychloroquine</p></li><li id="list-item-6"><p id="p-58">Overall, the results do not support the use of hydroxychloroquine in patients with persistent mild to moderate covid-19</p></li></ul></div></div></div></div><div class="section ack" id="ack-1"><h2>Acknowledgments</h2><p id="p-59">We thank the members of the trial steering committee for their many contributions in conducting the trial under very challenging field conditions—in particular, Yiping Xu and the members of the independent data and safety monitoring committee (Shenghan Lai (chair), Weimin Li, Hejian Zou, Xinxin Zhang, and Gang Chen) for their oversight; the chief of the Department of Anesthesiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Yan Luo, for her support of the trial; Xia Chen, Li Li, and Jian Li for their support of statistical analysis; the other members of the coordinating centres: Ming Li, Yongcai Gao, Ming Wu, Zuohan Xiao, Shanshan Deng, Xu Zhang, Xiaobo Chen, Haiyan Hang, Haiguang Xin, Yadong Gao, Dandan Dong, Mingjie Hou, Qiuping Peng, Yiming Yan, Peng Gao, Lin Sun, Jingdong Shi, Hong Tang, and Fei Deng; the donation of our study drug from the Shanghai Pharmaceuticals Holding; and the patients themselves for their bravery and altruism in participating in this trial. This manuscript been deposited at medRxiv as a preprint (<a href="https://doi.org/10.1101/2020.04.10.20060558">https://doi.org/10.1101/2020.04.10.20060558</a>).</p></div><div class="section fn-group" id="fn-group-1"><h2>Footnotes</h2><ul><li class="fn-participating-researchers" id="fn-3"><p id="p-60">Contributors: WT, ZC, MH, and ZW contributed equally to this paper and share joint first authorship. QX, GS, GN, and JQ contributed equally to this paper and share joint corresponding authorship. QX and GS were co-chief investigators of this trial. QX, GS, GN, and JQ led the development of the research question and study design and obtained the funding. WT, GS, QX, GN, JQ, and LL coordinated the operational delivery of the study protocol to the coordinating centres. LL led the process of data cleaning and analysis and took responsibility for the results in this manuscript and future analysis. ZC led and produced the first draft of this manuscript. MH, ZW, JC, WS, YW, WX, SL, EC, WC, XW, JY, JL, QZ, YY, ZX, DL, and YY represented the collaborating coordinating centres responsible for their centres’ participation in the trial. All authors provided critical review and final approval of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. QX and GS are the guarantors.</p></li><li class="fn-financial-disclosure" id="fn-4"><p id="p-61">Funding: This work was supported by the Emergent Projects of National Science and Technology (2020YFC0844500), National Natural Science Foundation of China (81970020, 81770025), National Key Research and Development Program of China (2016YFC0901104), Shanghai Municipal Key Clinical Specialty (shslczdzk02202, shslczdzk01103), National Innovative Research Team of High-level Local Universities in Shanghai, Shanghai Key Discipline for Respiratory Diseases (2017ZZ02014), National Major Scientific and Technological Special Project for Significant New Drugs Development (2017ZX09304007), Key Projects in the National Science and Technology Pillar Program during the Thirteenth Five-year Plan Period (2018ZX09206005-004, 2017ZX10202202-005-004, 2017ZX10203201-008). The funders played no role in study design, data collection, data analysis, data interpretation, or reporting. The guarantors had full access to all the data in the study, take responsibility for the integrity of the data and the accuracy of the data analysis, and had final responsibility for the decision to submit for publication.</p></li><li class="fn-conflict" id="fn-5"><p id="p-62">Competing interests: All authors have completed the ICMJE uniform disclosure form at <a href="http://www.icmje.org/coi_disclosure.pdf">www.icmje.org/coi_disclosure.pdf</a> and declare: no support from any organisation for the submitted work other than those listed above; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.</p></li><li class="fn-other" id="fn-6"><p id="p-63">Ethical approval: The trial was approved by the Institutional Review Board of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (KY2020–29). All patients gave written informed consent.</p></li><li class="fn-other" id="fn-7"><p id="p-64">Data sharing: Anonymised datasets can be made available on reasonable request after approval from the trial management committee and after signing of a data access agreement. Proposals should be directed to the corresponding author.</p></li><li class="fn-other" id="fn-8"><p id="p-65">The lead authors (the manuscript’s guarantors) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.</p></li><li class="fn-other" id="fn-9"><p id="p-66">Dissemination to participants and related patient and public communities: There are no plans to disseminate the results of the research to study participants or the relevant patient community.</p></li></ul></div><div class="license" id="license-1"><span class="ali-license-ref"><a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a></span><p id="p-1">This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p></div><div class="section ref-list" id="ref-list-1"><h2>References</h2><ol class="cit-list"><li><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1 in text" id="ref-1">↵</a><div class="cit ref-cit ref-web" id="cit-369.may14_5.m1849.1"><div class="cit-metadata unstructured">Coronavirus covid-19 global cases by Johns Hopkins CSSE. <a href="https://www.arcgis.com/apps/opsdashboard/index.html#/85320e2ea5424dfaaa75ae62e5c06e61">https://www.arcgis.com/apps/opsdashboard/index.html#/85320e2ea5424dfaaa75ae62e5c06e61</a>.</div><div class="cit-extra"></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference 2 in text" id="ref-2">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.2" data-doi="10.1007/s40265-017-0830-1"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Dyall</span>  <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Gross</span>  <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kindrachuk</span>  <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-etal">et al</span></li></ol><cite>. <span class="cit-article-title">Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies</span>. <abbr class="cit-jnl-abbrev">Drugs</abbr><span class="cit-pub-date">2017</span>;<span class="cit-vol">77</span>:<span class="cit-fpage">1935</span>-<span class="cit-lpage">66</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1007/s40265-017-0830-1</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>29143192</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DDrugs%26rft.volume%253D77%26rft.spage%253D1935%26rft_id%253Dinfo%253Adoi%252F10.1007%252Fs40265-017-0830-1%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1007/s40265-017-0830-1&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=http://www.n&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference 3 in text" id="ref-3">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.3" data-doi="10.1056/NEJMoa2001282"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Cao</span>  <span class="cit-name-given-names">B</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Wang</span>  <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Wen</span>  <span class="cit-name-given-names">D</span></span>, </li><li><span class="cit-etal">et al</span></li></ol><cite>. <span class="cit-article-title">A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr><span class="cit-pub-date">2020</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1056/NEJMoa2001282</span>.</cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa2001282%26rft_id%253Dinfo%253Apmid%252F32187464%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1056/NEJMoa2001282&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=32187464&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference 4 in text" id="ref-4">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.4" data-doi="10.1038/s41422-020-0282-0"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Wang</span>  <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Cao</span>  <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Zhang</span>  <span class="cit-name-given-names">L</span></span>, </li><li><span class="cit-etal">et al</span></li></ol><cite>. <span class="cit-article-title">Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</span>. <abbr class="cit-jnl-abbrev">Cell Res</abbr><span class="cit-pub-date">2020</span>;<span class="cit-vol">30</span>:<span class="cit-fpage">269</span>-<span class="cit-lpage">71</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1038/s41422-020-0282-0</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>32020029</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DCell%2BRes%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41422-020-0282-0%26rft_id%253Dinfo%253Apmid%252F32020029%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1038/s41422-020-0282-0&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=32020029&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference 5 in text" id="ref-5">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.5" data-doi="10.1093/cid/ciaa237"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Yao</span>  <span class="cit-name-given-names">X</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Ye</span>  <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Zhang</span>  <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-etal">et al</span></li></ol><cite>. <span class="cit-article-title">In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</span>. <abbr class="cit-jnl-abbrev">Clin Infect Dis</abbr><span class="cit-pub-date">2020</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1093/cid/ciaa237</span>.</cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DClin%2BInfect%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fcid%252Fciaa237%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1093/cid/ciaa237&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=http://www.n&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference 6 in text" id="ref-6">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.6" data-doi="10.5582/bst.2020.01047"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Gao</span>  <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Tian</span>  <span class="cit-name-given-names">Z</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yang</span>  <span class="cit-name-given-names">X</span></span></li></ol><cite>. <span class="cit-article-title">Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of covid-19 associated pneumonia in clinical studies</span>. <abbr class="cit-jnl-abbrev">Biosci Trends</abbr><span class="cit-pub-date">2020</span>;<span class="cit-vol">14</span>:<span class="cit-fpage">72</span>-<span class="cit-lpage">3</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.5582/bst.2020.01047</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>32074550</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DBiosci%2BTrends%26rft_id%253Dinfo%253Adoi%252F10.5582%252Fbst.2020.01047%26rft_id%253Dinfo%253Apmid%252F32074550%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.5582/bst.2020.01047&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=32074550&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7 in text" id="ref-7">↵</a><div class="cit ref-cit ref-web" id="cit-369.may14_5.m1849.7"><div class="cit-metadata unstructured">National Health Commission of the People’s Republic of China. Chinese guideline for the management COVID-19 (version 7.0, in Chinese). 2020. <a href="http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf">http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf</a>.</div><div class="cit-extra"></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8 in text" id="ref-8">↵</a><div class="cit ref-cit ref-web" id="cit-369.may14_5.m1849.8"><div class="cit-metadata unstructured">US Food and Drug Administration. Emergency Use Authorization. Hydroxychloroquine sulfate health care provider fact sheet. <a href="https://www.fda.gov/media/136534/download">https://www.fda.gov/media/136534/download</a>.</div><div class="cit-extra"></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9 in text" id="ref-9">↵</a><div class="cit ref-cit ref-web" id="cit-369.may14_5.m1849.9"><div class="cit-metadata unstructured">Piller C. “This is insane!” Many scientists lament Trump's embrace of risky malaria drugs for coronavirus. 2020. <a href="https://www.sciencemag.org/news/2020/03/insane-many-scientists-lament-trump-s-embrace-risky-malaria-drugs-coronavirus#">https://www.sciencemag.org/news/2020/03/insane-many-scientists-lament-trump-s-embrace-risky-malaria-drugs-coronavirus#</a>.</div><div class="cit-extra"></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10 in text" id="ref-10">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.10" data-doi="10.1007/s10787-015-0239-y"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Rainsford</span>  <span class="cit-name-given-names">KD</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Parke</span>  <span class="cit-name-given-names">AL</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Clifford-Rashotte</span>  <span class="cit-name-given-names">M</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Kean</span>  <span class="cit-name-given-names">WF</span></span></li></ol><cite>. <span class="cit-article-title">Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases</span>. <abbr class="cit-jnl-abbrev">Inflammopharmacology</abbr><span class="cit-pub-date">2015</span>;<span class="cit-vol">23</span>:<span class="cit-fpage">231</span>-<span class="cit-lpage">69</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1007/s10787-015-0239-y</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>26246395</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DInflammopharmacology%26rft.volume%253D23%26rft.spage%253D231%26rft_id%253Dinfo%253Adoi%252F10.1007%252Fs10787-015-0239-y%26rft_id%253Dinfo%253Apmid%252F26246395%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1007/s10787-015-0239-y&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=26246395&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11 in text" id="ref-11">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.11" data-doi="10.1056/NEJMe2005477"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Baden</span>  <span class="cit-name-given-names">LR</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Rubin</span>  <span class="cit-name-given-names">EJ</span></span></li></ol><cite>. <span class="cit-article-title">Covid-19 - the search for effective therapy</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr><span class="cit-pub-date">2020</span>:<span class="cit-fpage">1</span>-<span class="cit-lpage">2</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1056/NEJMe2005477</span>.</cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMe2005477%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1056/NEJMe2005477&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12 in text" id="ref-12">↵</a><div class="cit ref-cit ref-web" id="cit-369.may14_5.m1849.12"><div class="cit-metadata unstructured">National Health Commission of the People’s Republic of China. Chinese guideline for the management covid-19 (version 5.0, in Chinese). 2020. <a href="http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab6bec7f93e64e7f998d802991203cd6.pdf">http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab6bec7f93e64e7f998d802991203cd6.pdf</a>.</div><div class="cit-extra"></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13 in text" id="ref-13">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.13" data-doi="10.1136/bmj.m1091"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Chen</span>  <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Wu</span>  <span class="cit-name-given-names">D</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Chen</span>  <span class="cit-name-given-names">H</span></span>, </li><li><span class="cit-etal">et al</span></li></ol><cite>. <span class="cit-article-title">Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [correction in: <em>BMJ</em> 2020;368:m1295]</span>. <abbr class="cit-jnl-abbrev">BMJ</abbr><span class="cit-pub-date">2020</span>;<span class="cit-vol">368</span>:<span class="cit-fpage">m1091</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1136/bmj.m1091</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>32217556</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DBMJ%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fbmj.m1091%26rft_id%253Dinfo%253Apmid%252F32217556%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE4OiIzNjgvbWFyMjZfMTAvbTEwOTEiO3M6NDoiYXRvbSI7czoyMzoiL2Jtai8zNjkvYm1qLm0xODQ5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink"><span><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14 in text" id="ref-14">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.14" data-doi="10.1136/bmj.m1443"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Zheng</span>  <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Fan</span>  <span class="cit-name-given-names">J</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Yu</span>  <span class="cit-name-given-names">F</span></span>, </li><li><span class="cit-etal">et al</span></li></ol><cite>. <span class="cit-article-title">Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study</span>. <abbr class="cit-jnl-abbrev">BMJ</abbr><span class="cit-pub-date">2020</span>;<span class="cit-vol">369</span>:<span class="cit-fpage">m1443</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1136/bmj.m1443</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>32317267</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DBMJ%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fbmj.m1443%26rft_id%253Dinfo%253Apmid%252F32317267%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE4OiIzNjkvYXByMjFfMjAvbTE0NDMiO3M6NDoiYXRvbSI7czoyMzoiL2Jtai8zNjkvYm1qLm0xODQ5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink"><span><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15 in text" id="ref-15">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.15" data-doi="10.1086/598513"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Harper</span>  <span class="cit-name-given-names">SA</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Bradley</span>  <span class="cit-name-given-names">JS</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Englund</span>  <span class="cit-name-given-names">JA</span></span>, </li><li><span class="cit-etal">et al.</span>, </li><li><span class="cit-auth cit-collab">Expert Panel of the Infectious Diseases Society of America</span></li></ol><cite>. <span class="cit-article-title">Seasonal influenza in adults and children–diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America</span>. <abbr class="cit-jnl-abbrev">Clin Infect Dis</abbr><span class="cit-pub-date">2009</span>;<span class="cit-vol">48</span>:<span class="cit-fpage">1003</span>-<span class="cit-lpage">32</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1086/598513</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>19281331</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DClin%2BInfect%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1086%252F598513%26rft_id%253Dinfo%253Apmid%252F19281331%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1086/598513&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=19281331&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a><a href="/lookup/external-ref?access_num=000264307400001&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience"><span>Web of Science</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference 16 in text" id="ref-16">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.16" data-doi="10.1002/art.10307"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Munster</span>  <span class="cit-name-given-names">T</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Gibbs</span>  <span class="cit-name-given-names">JP</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Shen</span>  <span class="cit-name-given-names">D</span></span>, </li><li><span class="cit-etal">et al</span></li></ol><cite>. <span class="cit-article-title">Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis</span>. <abbr class="cit-jnl-abbrev">Arthritis Rheum</abbr><span class="cit-pub-date">2002</span>;<span class="cit-vol">46</span>:<span class="cit-fpage">1460</span>-<span class="cit-lpage">9</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1002/art.10307</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>12115175</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DMunster%26rft.auinit1%253DT.%26rft.volume%253D46%26rft.issue%253D6%26rft.spage%253D1460%26rft.epage%253D1469%26rft.atitle%253DHydroxychloroquine%2Bconcentration-response%2Brelationships%2Bin%2Bpatients%2Bwith%2Brheumatoid%2Barthritis.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.10307%26rft_id%253Dinfo%253Apmid%252F12115175%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1002/art.10307&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=12115175&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a><a href="/lookup/external-ref?access_num=000176199200006&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience"><span>Web of Science</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17 in text" id="ref-17">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.17" data-doi="10.1016/j.ajo.2015.07.012"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Leung</span>  <span class="cit-name-given-names">LS</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Neal</span>  <span class="cit-name-given-names">JW</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Wakelee</span>  <span class="cit-name-given-names">HA</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Sequist</span>  <span class="cit-name-given-names">LV</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Marmor</span>  <span class="cit-name-given-names">MF</span></span></li></ol><cite>. <span class="cit-article-title">Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy</span>. <abbr class="cit-jnl-abbrev">Am J Ophthalmol</abbr><span class="cit-pub-date">2015</span>;<span class="cit-vol">160</span>:<span class="cit-fpage">799</span>-<span class="cit-lpage">805.e1</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1016/j.ajo.2015.07.012</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>26189086</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DAm%2BJ%2BOphthalmol%26rft.volume%253D160%26rft.spage%253D799%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.ajo.2015.07.012%26rft_id%253Dinfo%253Apmid%252F26189086%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1016/j.ajo.2015.07.012&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=26189086&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18 in text" id="ref-18">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.18" data-doi="10.1016/j.clinthera.2009.08.009"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">van Roon</span>  <span class="cit-name-given-names">EN</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">van den Bemt</span>  <span class="cit-name-given-names">PM</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Jansen</span>  <span class="cit-name-given-names">TL</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Houtman</span>  <span class="cit-name-given-names">NM</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">van de Laar</span>  <span class="cit-name-given-names">MA</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Brouwers</span>  <span class="cit-name-given-names">JR</span></span></li></ol><cite>. <span class="cit-article-title">An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists</span>. <abbr class="cit-jnl-abbrev">Clin Ther</abbr><span class="cit-pub-date">2009</span>;<span class="cit-vol">31</span>:<span class="cit-fpage">1737</span>-<span class="cit-lpage">46</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1016/j.clinthera.2009.08.009</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>19808132</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DClinical%2Btherapeutics%26rft.stitle%253DClin%2BTher%26rft.aulast%253Dvan%2BRoon%26rft.auinit1%253DE.%2BN.%26rft.volume%253D31%26rft.issue%253D8%26rft.spage%253D1737%26rft.epage%253D1746%26rft.atitle%253DAn%2Bevidence-based%2Bassessment%2Bof%2Bthe%2Bclinical%2Bsignificance%2Bof%2Bdrug-drug%2Binteractions%2Bbetween%2Bdisease-modifying%2Bantirheumatic%2Bdrugs%2Band%2Bnon-antirheumatic%2Bdrugs%2Baccording%2Bto%2Brheumatologists%2Band%2Bpharmacists.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.clinthera.2009.08.009%26rft_id%253Dinfo%253Apmid%252F19808132%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1016/j.clinthera.2009.08.009&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=19808132&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19 in text" id="ref-19">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.19" data-doi="10.1056/NEJMoa040582"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Ray</span>  <span class="cit-name-given-names">WA</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Murray</span>  <span class="cit-name-given-names">KT</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Meredith</span>  <span class="cit-name-given-names">S</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Narasimhulu</span>  <span class="cit-name-given-names">SS</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Hall</span>  <span class="cit-name-given-names">K</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Stein</span>  <span class="cit-name-given-names">CM</span></span></li></ol><cite>. <span class="cit-article-title">Oral erythromycin and the risk of sudden death from cardiac causes</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr><span class="cit-pub-date">2004</span>;<span class="cit-vol">351</span>:<span class="cit-fpage">1089</span>-<span class="cit-lpage">96</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1056/NEJMoa040582</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>15356306</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DNew%2BEngland%2BJournal%2Bof%2BMedicine%26rft.stitle%253DNEJM%26rft.aulast%253DRay%26rft.auinit1%253DW.%2BA.%26rft.volume%253D351%26rft.issue%253D11%26rft.spage%253D1089%26rft.epage%253D1096%26rft.atitle%253DOral%2BErythromycin%2Band%2Bthe%2BRisk%2Bof%2BSudden%2BDeath%2Bfrom%2BCardiac%2BCauses%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa040582%26rft_id%253Dinfo%253Apmid%252F15356306%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1056/NEJMoa040582&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=15356306&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a><a href="/lookup/external-ref?access_num=000223733900008&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience"><span>Web of Science</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference 20 in text" id="ref-20">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.20" data-doi="10.1086/508873"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Owens</span>  <span class="cit-name-given-names">RC</span>  <span class="cit-name-suffix">Jr</span>.</span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Nolin</span>  <span class="cit-name-given-names">TD</span></span></li></ol><cite>. <span class="cit-article-title">Antimicrobial-associated QT interval prolongation: pointes of interest</span>. <abbr class="cit-jnl-abbrev">Clin Infect Dis</abbr><span class="cit-pub-date">2006</span>;<span class="cit-vol">43</span>:<span class="cit-fpage">1603</span>-<span class="cit-lpage">11</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1086/508873</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>17109296</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DClinical%2BInfectious%2BDiseases%26rft.stitle%253DClinical%2BInfectious%2BDiseases%26rft.aulast%253DOwens%26rft.auinit1%253DR.%2BC.%26rft.volume%253D43%26rft.issue%253D12%26rft.spage%253D1603%26rft.epage%253D1611%26rft.atitle%253DAntimicrobial-associated%2BQT%2Binterval%2Bprolongation%253A%2Bpointes%2Bof%2Binterest.%26rft_id%253Dinfo%253Adoi%252F10.1086%252F508873%26rft_id%253Dinfo%253Apmid%252F17109296%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1086/508873&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=17109296&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a><a href="/lookup/external-ref?access_num=000242126300013&amp;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience"><span>Web of Science</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference 21 in text" id="ref-21">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.21" data-doi="10.1038/s41584-020-0372-x"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Schrezenmeier</span>  <span class="cit-name-given-names">E</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Dörner</span>  <span class="cit-name-given-names">T</span></span></li></ol><cite>. <span class="cit-article-title">Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology</span>. <abbr class="cit-jnl-abbrev">Nat Rev Rheumatol</abbr><span class="cit-pub-date">2020</span>;<span class="cit-vol">16</span>:<span class="cit-fpage">155</span>-<span class="cit-lpage">66</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1038/s41584-020-0372-x</span> <span class="cit-pub-id cit-pub-id-pmid"><span class="cit-pub-id-scheme-pmid">pmid:</span>32034323</span></cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DNat%2BRev%2BRheumatol%26rft.volume%253D16%26rft.spage%253D155%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41584-020-0372-x%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1038/s41584-020-0372-x&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=http://www.n&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li><li><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference 22 in text" id="ref-22">↵</a><div class="cit ref-cit ref-journal" id="cit-369.may14_5.m1849.22" data-doi="10.1001/jama.2020.3786"><div class="cit-metadata"><ol class="cit-auth-list"><li><span class="cit-auth"><span class="cit-name-surname">Wang</span>  <span class="cit-name-given-names">W</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Xu</span>  <span class="cit-name-given-names">Y</span></span>, </li><li><span class="cit-auth"><span class="cit-name-surname">Gao</span>  <span class="cit-name-given-names">R</span></span>, </li><li><span class="cit-etal">et al</span></li></ol><cite>. <span class="cit-article-title">Detection of SARS-CoV-2 in different types of clinical specimens</span>. <abbr class="cit-jnl-abbrev">JAMA</abbr><span class="cit-pub-date">2020</span>.<span class="cit-pub-id-sep cit-pub-id-doi-sep"> </span><span class="cit-pub-id cit-pub-id-doi"><span class="cit-pub-id-scheme-doi">doi:</span>10.1001/jama.2020.3786</span>.</cite></div><div class="cit-extra"><a href="{openurl}?query=rft.jtitle%253DJAMA%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.2020.3786%26rft_id%253Dinfo%253Apmid%252F32159775%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url"><span>OpenUrl</span></a><a href="/lookup/external-ref?access_num=10.1001/jama.2020.3786&amp;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref"><span>CrossRef</span></a><a href="/lookup/external-ref?access_num=32159775&amp;link_type=MED&amp;atom=%2Fbmj%2F369%2Fbmj.m1849.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline"><span>PubMed</span></a></div></div></li></ol></div><span class="highwire-journal-article-marker-end"></span></div><span id="related-urls"></span></div></div>  </div>

  
  </div>
</div>
  </div>
</div>
</div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-article-trendmd"  >
  
      
  
  <div class="pane-content">
    <div id="trendmd-suggestions"></div>  </div>

  
  </div>
        </article>
      </div>
      <div class="right-nav col-xs-12 col-sm-4 col-md-4 col-lg-4">
        <aside>
          <div class="panel-pane pane-service-links"  >
  
      
  
  <div class="pane-content">
    <div class="service-links"><ul><li class="first"><a href="http://twitter.com/share?url=https%3A//www.bmj.com/content/369/bmj.m1849&amp;count=horizontal&amp;via=&amp;text=Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019%3A%20open%20label%2C%20randomised%20controlled%20trial&amp;counturl=https%3A//www.bmj.com/content/369/bmj.m1849" class="twitter-share-button service-links-twitter-widget" id="twitter_widget" title="Tweet This" rel="nofollow"><span class="element-invisible">Tweet Widget</span></a></li>
<li class="last"><a href="http://www.facebook.com/plugins/like.php?href=https%3A//www.bmj.com/content/369/bmj.m1849&amp;layout=button_count&amp;show_faces=false&amp;action=like&amp;colorscheme=light&amp;width=100&amp;height=21&amp;font=&amp;locale=" id="facebook_like" title="I Like it" class="service-links-facebook-like" rel="nofollow"><span class="element-invisible">Facebook Like</span></a></li>
</ul></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-snippet"  >
  
      
  
  <div class="pane-content">
    <div class="oas-ad-middle-1" id="oas-ad-middle-1">
  
      
  <div class="snippet-content">
    <div id="div-gpt-ad-7326006-2"><script>
    googletag.cmd.push(function() { googletag.display('div-gpt-ad-7326006-2'); });
  </script></div>
  </div>

</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-bmj-issue-link"  >
  
      
  
  <div class="pane-content">
    <a href="/content/369/8248" class="btn btn-primary" target="_blank">See other articles in issue 8248</a>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-bmj-article-buttons"  >
  
        <h2 class="pane-title">
      Article tools    </h2>
    
  
  <div class="pane-content">
    <a href="/content/369/bmj.m1849.full.pdf" title="PDF" class="pdf-link"><span class="icon"><em class="bmj-icon blue-icon fa fa-file-text"></em>PDF</span></a><a href="/content/369/bmj.m1849/rapid-responses" class="citation-rr-link"><em class="bmj-icon blue-icon fa fa-comment"></em>10 responses</a>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-bmj-article-custom-meta"  >
  
      
  
  <div class="pane-content">
    <a href="//resources.bmj.com/bmj/authors/fast-track-publication" title="fast track"><img class="fast-track" title="fast track" src="https://www.bmj.com/sites/default/modules/jnl-bmj/jnl_bmj/plugins/content_types/bmj_article_custom_meta_images/fast-track.jpg" /></a>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-panels-mini pane-jnl-bmj-art-tools"  >
  
      
  
  <div class="pane-content">
    <div class="panel-display panel-1col clearfix" id="mini-panel-jnl_bmj_art_tools">
  <div class="panel-panel panel-col">
    <div><ul><li class="first"><div class="panel-pane pane-custom pane-1"  >
  
      
  
  <div class="pane-content">
    <p><i class="bmj-icon fa fa-edit"></i><a href="/content/369/bmj.m1849/submit-a-rapid-response">Respond to this article</a></p>
  </div>

  
  </div>
</li>
<li><div class="panel-pane pane-bmj-article-fig-data-link"  >
  
      
  
  <div class="pane-content">
    <i class="bmj-icon fa fa-plus"></i><a href="/content/369/bmj.m1849/related#datasupp">Data supplement</a>  </div>

  
  </div>
</li>
<li><div class="panel-pane pane-bmj-variant-link"  >
  
      
  
  <div class="pane-content">
    <i class="bmj-icon fa fa-print"></i><a href="/content/369/bmj.m1849.full-text.print" data-font-icon="fa fa-print">Print</a>  </div>

  
  </div>
</li>
<li><div class="panel-pane pane-bmj-minipanel-model-link pane-jnl-bmj-article-page-alerts"  >
  
      
  
  <div class="pane-content">
    <div class='minipanel-model-wrapper'><div class='minipanel-model-link-link'><i class="bmj-icon fa fa-bullhorn"></i><a href="/#mini-panel-jnl-bmj-article-page-alerts-1" data-toggle="collapse" role="button" data-font-icon="fa fa-bullhorn">Alerts & updates</a></div><!-- Collapse --><div id="mini-panel-jnl-bmj-article-page-alerts-1" class="panel-collapse collapse"><div class="minipanel-header"><h4 class="minipanel-label">Article alerts</h4><div class="short-description"><div class="alerts-marketing">Please note: your email address is provided to the journal, which may use this information for marketing purposes.</div></div></div><div class="minipanel-body"><div class="panel-display row bootstrap-onecol" id="mini-panel-jnl_bmj_article_page_alerts">
  <div class="panel-panel col-xs-12 col-sm-12 col-md-12 col-lg-12">
    <div class="panel-pane pane-custom pane-2"  >
  
      
  
  <div class="pane-content">
    <h4 class="minipanel-label">Log in or register:</h4>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-alerts-login-form"  >
  
      
  
  <div class="pane-content">
    <form action="/content/369/bmj.m1849?tab=article-alert" method="post" id="user-login-form" accept-charset="UTF-8"><div><div class="form-type-textfield form-item-name form-item form-group">
  <label for="edit-name">Username <span class="form-required" title="This field is required.">*</span></label>
 <input class="form-control form-text required" type="text" id="edit-name" name="name" value="" size="15" maxlength="60" />
</div>
<div class="form-type-password form-item-pass form-item form-group">
  <label for="edit-pass">Password <span class="form-required" title="This field is required.">*</span></label>
 <input class="form-control form-text required" type="password" id="edit-pass" name="pass" size="15" maxlength="128" />
</div>
<input type="hidden" name="form_build_id" value="form-ICfIXgvqI9iAIMauwnudjoTvPKSioIbwcryUQCz42r8" />
<input type="hidden" name="form_id" value="highwire_alerts_user_login" />
<input class="btn form-submit" type="submit" id="edit-submit" name="op" value="Log in" /></div></form>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-custom pane-3"  id="register-for-alerts" >
  
      
  
  <div class="pane-content">
    <p><a class="btn register-button" href="//myaccount.bmj.com/myaccount/registration.html?regService=bmj-registration&amp;fwdUrl=https://www.bmj.com/content/369/bmj.m1849?tab=article-alert&amp;itemId=pr1906">Register for alerts</a><br />
<div class="alerts-email"><i class="fa fa-info-circle"></i> If you have registered for alerts, you should use your registered email address as your username</div>
  </div>

  
  </div>
  </div>
</div>
</div></div></div>  </div>

  
  </div>
</li>
<li><div class="panel-pane pane-bmj-minipanel-model-link pane-article-page-citation-download"  >
  
      
  
  <div class="pane-content">
    <div class='minipanel-model-wrapper'><div class='minipanel-model-link-link'><i class="bmj-icon fa fa-globe"></i><a href="/#mini-panel-article-page-citation-download-1" data-toggle="collapse" role="button" data-font-icon="fa fa-globe">Citation tools</a></div><!-- Collapse --><div id="mini-panel-article-page-citation-download-1" class="panel-collapse collapse"><div class="minipanel-header"><h4 class="minipanel-label">Download this article to citation manager</h4></div><div class="minipanel-body"><div class="panel-display row bootstrap-onecol" id="mini-panel-article_page_citation_download">
  <div class="panel-panel col-xs-12 col-sm-12 col-md-12 col-lg-12">
    <div class="panel-pane pane-bmj-citation-export"  >
  
      
  
  <div class="pane-content">
    <div>  
  <div class="highwire-citation-info">
      <div class="highwire-article-citation highwire-citation-type-highwire-article node1027155--3" data-node-nid="1027155" id="node-1027155--41418220760" data-pisa="bmj;369/may14_5/m1849" data-pisa-master="bmj;bmj.m1849" data-apath="/bmj/369/bmj.m1849.atom"><div id="jnl_bmj_custom_authors" style="display: none;"><span data-delta="0"><span class="nlm-given-names">Wei</span> <span class="nlm-surname">Tang</span> <span class="nlm-role">associate professor</span></span>, <span data-delta="1"><span class="nlm-given-names">Zhujun</span> <span class="nlm-surname">Cao</span> <span class="nlm-role">infectious diseases physician</span></span>, <span data-delta="2"><span class="nlm-given-names">Mingfeng</span> <span class="nlm-surname">Han</span> <span class="nlm-role">chest physician</span></span>, <span data-delta="3"><span class="nlm-given-names">Zhengyan</span> <span class="nlm-surname">Wang</span> <span class="nlm-role">chest physician</span></span>, <span data-delta="4"><span class="nlm-given-names">Junwen</span> <span class="nlm-surname">Chen</span> <span class="nlm-role">chest physician</span></span>, <span data-delta="5"><span class="nlm-given-names">Wenjin</span> <span class="nlm-surname">Sun</span> <span class="nlm-role">infectious diseases physician</span></span> et al</div>
<div  class="highwire-cite highwire-cite-highwire-article highwire-citation-bmj-article-citation-export clearfix" >
  
      <span  class="highwire-cite-authors" ><!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<html><body><span data-delta="0"><span class="nlm-surname">Tang</span> <span class="nlm-given-names">W</span></span>, <span data-delta="1"><span class="nlm-surname">Cao</span> <span class="nlm-given-names">Z</span></span>, <span data-delta="2"><span class="nlm-surname">Han</span> <span class="nlm-given-names">M</span></span>, <span data-delta="3"><span class="nlm-surname">Wang</span> <span class="nlm-given-names">Z</span></span>, <span data-delta="4"><span class="nlm-surname">Chen</span> <span class="nlm-given-names">J</span></span>, <span data-delta="5"><span class="nlm-surname">Sun</span> <span class="nlm-given-names">W</span></span> et al. </body></html>
</span>
  
      <span class="highwire-cite-title article-title">Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial</span>  
  
      <span  class="highwire-cite-metadata" ><span  class="highwire-cite-metadata-journal highwire-cite-metadata">BMJ  </span><span  class="highwire-cite-metadata-date highwire-cite-metadata">2020;  </span><span  class="highwire-cite-metadata-volume highwire-cite-metadata">369 </span><span  class="highwire-cite-metadata-volume highwire-cite-metadata">:m1849 </span></span>
  
      <span  class="article-doi" >doi:10.1136/bmj.m1849</span>
  
  
  </div>
</div>  </div>
  <div class="highwire-citation-formats">
  	    <div class="highwire-citation-formats-links">
      <span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.spage&amp;rft.epage&amp;rft.atitle=Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019%3A%20open%20label%2C%20randomised%20controlled%20trial&amp;rft.volume=369&amp;rft.issue&amp;rft.date=2020-05-14%2022%3A31%3A18&amp;rft.stitle&amp;rft.jtitle=BMJ&amp;rft.au=Tang%2C+Wei&amp;rft.au=Cao%2C+Zhujun&amp;rft.au=Han%2C+Mingfeng&amp;rft.au=Wang%2C+Zhengyan&amp;rft.au=Chen%2C+Junwen&amp;rft.au=Sun%2C+Wenjin&amp;rft.au=Wu%2C+Yaojie&amp;rft.au=Xiao%2C+Wei&amp;rft.au=Liu%2C+Shengyong&amp;rft.au=Chen%2C+Erzhen&amp;rft.au=Chen%2C+Wei&amp;rft.au=Wang%2C+Xiongbiao&amp;rft.au=Yang%2C+Jiuyong&amp;rft.au=Lin%2C+Jun&amp;rft.au=Zhao%2C+Qingxia&amp;rft.au=Yan%2C+Youqin&amp;rft.au=Xie%2C+Zhibin&amp;rft.au=Li%2C+Dan&amp;rft.au=Yang%2C+Yaofeng&amp;rft.au=Liu%2C+Leshan&amp;rft.au=Qu%2C+Jieming&amp;rft.au=Ning%2C+Guang&amp;rft.au=Shi%2C+Guochao&amp;rft.au=Xie%2C+Qing"></span><h3></h3><ul class="bmj-citation-links"><li class="first">BibTeX (win & mac)<a href="/highwire/citation/1027155/bibtext" class="citation-link btn btn-primary pull-right">Download</a></li>
<li>EndNote (tagged)<a href="/highwire/citation/1027155/endnote-tagged" class="citation-link btn btn-primary pull-right">Download</a></li>
<li>EndNote 8 (xml)<a href="/highwire/citation/1027155/endnote-8-xml" class="citation-link btn btn-primary pull-right">Download</a></li>
<li>RefWorks Tagged (win & mac)<a href="/highwire/citation/1027155/refworks-tagged" class="citation-link btn btn-primary pull-right">Download</a></li>
<li>RIS (win only)<a href="/highwire/citation/1027155/ris" class="citation-link btn btn-primary pull-right">Download</a></li>
<li class="last">Medlars<a href="/highwire/citation/1027155/medlars" class="citation-link btn btn-primary pull-right">Download</a></li>
</ul>    </div>
  </div>
</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-snippet"  >
  
        <h2 class="pane-title">
      Help    </h2>
    
  
  <div class="pane-content">
    <div class="jnl-bmj-citation-download-help" id="jnl-bmj-citation-download-help">
  
      
  <div class="snippet-content">
    <div class="citation-help">
  <p class="citation-manager">If you are unable to import citations, please contact
  technical support for your product directly (links go to external sites):</p>

  <ul>
    <li><a href="http://www.endnote.com/support/ensupport.asp">EndNote</a></li>

    <li><a href="http://www.procite.com/support/pcsupport.asp">ProCite</a></li>

    <li><a href="http://www.refman.com/support/rmsupport.asp">Reference
    Manager</a></li>

    <li><a href=
    "http://www.refworks.com/content/products/content.asp">RefWorks</a></li>

    <li><a href="http://www.zotero.org/support">Zotero</a></li>
  </ul>
</div>  </div>

</div>
  </div>

  
  </div>
  </div>
</div>
</div></div></div>  </div>

  
  </div>
</li>
<li class="last"><div class="panel-pane pane-bmj-permission-link"  >
  
      
  
  <div class="pane-content">
    <i class="bmj-icon icon-copyright"></i><a href="https://s100.copyright.com/AppDispatchServlet?publisherName=BMJ&amp;publication=bmj&amp;title=Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019%3A%20open%20label%2C%20randomised%20controlled%20trial&amp;publicationDate=05/14/2020&amp;author=Wei%20Tang%2C%20Zhujun%20Cao%2C%20Mingfeng%20Han%2C%20Zhengyan%20Wang%2C%20Junwen%20Chen%2C%20Wenjin%20Sun%2C%20Yaojie%20Wu%2C%20Wei%20Xiao%2C%20Shengyong%20Liu%2C%20Erzhen%20Chen%2C%20Wei%20Chen%2C%20Xiongbiao%20Wang%2C%20Jiuyong%20Yang%2C%20Jun%20Lin%2C%20Qingxia%20Zhao%2C%20Youqin%20Yan%2C%20Zhibin%20Xie%2C%20Dan%20Li%2C%20Yaofeng%20Yang%2C%20Leshan%20Liu%2C%20Jieming%20Qu%2C%20Guang%20Ning%2C%20Guochao%20Shi%2C%20Qing%20Xie&amp;contentID=10.1136/bmj.m1849&amp;volumeNum=369&amp;issueNum=&amp;startPage=&amp;endPage=&amp;copyright=BMJ%20Publishing%20Group%20Ltd&amp;oa=CC-BY-4.0&amp;orderBeanReset=1&amp;link_type=PERMISSIONDIRECT&amp;atom=/bmj/369/bmj.m1849.atom" rel="external" class="bmj-permission-link request-permissions" target="_blank" data-font-icon="icon-copyright">Request permissions</a>  </div>

  
  </div>
</li>
</ul></div>
  </div>
</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-panels-mini pane-bmj-article-share-modal"  >
  
      
  
  <div class="pane-content">
    <div class="panel-display row bootstrap-onecol" id="mini-panel-bmj_article_share_modal">
  <div class="panel-panel col-xs-12 col-sm-12 col-md-12 col-lg-12">
    <div class="panel-pane pane-bmj-article-links"  >
  
      
  
  <div class="pane-content">
    <div class="bmj-article-links minipanel-model-wrapper"><ul class="links"><li><div class="minipanel-model-link-link"><i class="bmj-icon fa fa-user"></i><a data-font-icon="fa fa-bullhorn" role="button" data-toggle="collapse" href="/#mini-panel-jnl-bmj-article-page-citation" class="collapsed">Author citation</a></div></li></ul><div style="height: 0px;" id="mini-panel-jnl-bmj-article-page-citation" class="panel-collapse collapse"><ul class="links"><li class="0 first"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Tang%20Wei%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Wei Tang</a></li>
<li class="1"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Cao%20Zhujun%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Zhujun Cao</a></li>
<li class="2"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Han%20Mingfeng%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Mingfeng Han</a></li>
<li class="3"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Wang%20Zhengyan%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Zhengyan Wang</a></li>
<li class="4"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Chen%20Junwen%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Junwen Chen</a></li>
<li class="5"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Sun%20Wenjin%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Wenjin Sun</a></li>
<li class="6"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Wu%20Yaojie%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Yaojie Wu</a></li>
<li class="7"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Xiao%20Wei%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Wei Xiao</a></li>
<li class="8"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Liu%20Shengyong%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Shengyong Liu</a></li>
<li class="9"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Chen%20Erzhen%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Erzhen Chen</a></li>
<li class="10"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Chen%20Wei%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Wei Chen</a></li>
<li class="11"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Wang%20Xiongbiao%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Xiongbiao Wang</a></li>
<li class="12"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Yang%20Jiuyong%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Jiuyong Yang</a></li>
<li class="13"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Lin%20Jun%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Jun Lin</a></li>
<li class="14"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Zhao%20Qingxia%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Qingxia Zhao</a></li>
<li class="15"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Yan%20Youqin%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Youqin Yan</a></li>
<li class="16"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Xie%20Zhibin%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Zhibin Xie</a></li>
<li class="17"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Li%20Dan%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Dan Li</a></li>
<li class="18"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Yang%20Yaofeng%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Yaofeng Yang</a></li>
<li class="19"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Liu%20Leshan%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Leshan Liu</a></li>
<li class="20"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Qu%20Jieming%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Jieming Qu</a></li>
<li class="21"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Ning%20Guang%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Guang Ning</a></li>
<li class="22"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Shi%20Guochao%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Guochao Shi</a></li>
<li class="23 last"><a href="//www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;term=Xie%20Qing%5Bau%5D&amp;dispmax=50" target="_blank">Articles by Qing Xie</a></li>
</ul></div></div><div class="bmj-article-links"><ul class="links"><li class="0 first last"><a href="//portfolio.bmj.com/portfolio/add-to-portfolio.html?t=Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019%3A%20open%20label%2C%20randomised%20controlled%20trial&amp;u=http%3A//www.bmj.com/content/369/bmj.m1849" target="_blank" id="add-to-bmj-portfolio" class="bmj-portfolio" rel="nofollow">Add article to BMJ Portfolio</a></li>
</ul></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-bmj-minipanel-model-link pane-jnl-bmj-article-button-email-to"  >
  
      
  
  <div class="pane-content">
    <div class='minipanel-model-wrapper'><div class='minipanel-model-link-link'><i class="bmj-icon icon-email"></i><a href="/#mini-panel-jnl-bmj-article-button-email-to-1" data-toggle="collapse" role="button" data-font-icon="icon-email">Email to a friend</a></div><!-- Collapse --><div id="mini-panel-jnl-bmj-article-button-email-to-1" class="panel-collapse collapse"><div class="minipanel-header"><h4 class="minipanel-label">Forward this page</h4></div><div class="minipanel-body"><div class="panel-display row bootstrap-onecol" id="mini-panel-jnl_bmj_article_button_email_to">
  <div class="panel-panel col-xs-12 col-sm-12 col-md-12 col-lg-12">
    <div class="panel-pane pane-block pane-forward-form"  >
  
      
  
  <div class="pane-content">
    <form action="/content/369/bmj.m1849" method="post" id="forward-form" accept-charset="UTF-8"><div><div id="edit-instructions" class="form-type-item form-item form-group">
 <p>Thank you for your interest in spreading the word about The BMJ.</p><p>NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.</p>
</div>
<div class="form-type-textfield form-item-name form-item form-group">
  <label for="edit-name--2">Username <span class="form-required" title="This field is required.">*</span></label>
 <input class="form-control form-text required" type="text" id="edit-name--2" name="name" value="" size="58" maxlength="256" />
</div>
<div class="form-type-textfield form-item-email form-item form-group">
  <label for="edit-email">Your Email <span class="form-required" title="This field is required.">*</span></label>
 <input class="form-control form-text required" type="text" id="edit-email" name="email" value="" size="58" maxlength="256" />
</div>
<div class="form-type-textarea form-item-recipients form-item form-group">
  <label for="edit-recipients">Send To <span class="form-required" title="This field is required.">*</span></label>
 <div class="form-textarea-wrapper"><textarea class="form-control form-textarea required" id="edit-recipients" name="recipients" cols="50" rows="3"></textarea></div>
</div>
<div id="edit-page" class="form-type-item form-item form-group">
  <label for="edit-page">You are going to email the following </label>
 <a href="/content/369/bmj.m1849" class="active">Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial</a>
</div>
<div class="form-type-textarea form-item-message form-item form-group">
  <label for="edit-message--2">Your Personal Message </label>
 <div class="form-textarea-wrapper"><textarea class="form-control form-textarea" id="edit-message--2" name="message" cols="50" rows="3"></textarea></div>
</div>
<input type="hidden" name="path" value="node/1027155" />
<input type="hidden" name="path_cid" value="" />
<input type="hidden" name="forward_footer" value=" " />
<input type="hidden" name="form_build_id" value="form-6TI-W9Glwe6xrOmfMVtxnWALbFe5b3I1yp6sOof1z3E" />
<input type="hidden" name="form_id" value="forward_form" />
<fieldset  class="captcha panel panel-default form-wrapper">
            <legend class="panel-heading">
        <div class="panel-title fieldset-legend">
          CAPTCHA        </div>
      </legend>
          <div class="panel-body">
          <p class="help-block">
        This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.      </p>
        <input type="hidden" name="captcha_sid" value="257893867" />
<input type="hidden" name="captcha_token" value="3ba6fd969bb73b7ccb3b297c831c2267" />
<input type="hidden" name="captcha_response" value="Google no captcha" />
<div class="g-recaptcha" data-sitekey="6LfnJVIUAAAAAE-bUOMg0MJGki4lqSvDmhJp19fN" data-theme="light" data-type="image"></div>  </div>
  </fieldset>
<input class="btn form-submit" type="submit" id="edit-submit--2" name="op" value="Send" /></div></form>  </div>

  
  </div>
  </div>
</div>
</div></div></div>  </div>

  
  </div>
  </div>
</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-panels-ajax-tab-tabs"  >
  
      
  
  <div class="pane-content">
    <ul class="tabs inline panels-ajax-tab"><li class="first"><a title="BMJ Feeds UK Jobs" href="/content/369/bmj.m1849" class="panels-ajax-tab-tab" data-panel-name="jnl_bmj_feeds_uk_jobs" data-target-id="panel_jobshome" data-entity-context="none" data-trigger="" data-url-enabled="0">UK jobs</a><a title="BMJ Feeds UK Jobs" href="/panels_ajax_tab/jnl_bmj_feeds_uk_jobs/none/0" rel="nofollow" style="display:none" class="js-crawler-link"></a></li>
<li class="last"><a title="BMJ Feeds International Jobs" href="/content/369/bmj.m1849" class="panels-ajax-tab-tab" data-panel-name="jnl_bmj_feeds_international_jobs" data-target-id="panel_jobshome" data-entity-context="none" data-trigger="jnl_bmj_feeds_international_jobs" data-url-enabled="0">International jobs</a><a title="BMJ Feeds International Jobs" href="/panels_ajax_tab/jnl_bmj_feeds_international_jobs/none/0" rel="nofollow" style="display:none" class="js-crawler-link"></a></li>
</ul>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-panels-ajax-tab-container"  >
  
      
  
  <div class="pane-content">
    <div data-panels-ajax-tab-preloaded="jnl_bmj_feeds_uk_jobs" id="panels-ajax-tab-container-panel_jobshome" class="panels-ajax-tab-container"><div class="panels-ajax-tab-loading" style ="display:none"><img class="loading" src="https://www.bmj.com/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif" alt="Loading" title="Loading" /></div><div class="panels-ajax-tab-wrap-jnl_bmj_feeds_uk_jobs"><div class="panel-display row bootstrap-onecol" >
  <div class="panel-panel col-xs-12 col-sm-12 col-md-12 col-lg-12">
    <div class="panel-pane pane-jnl-bmj-feed2widget"  >
  
      
  
  <div class="pane-content">
      <div class="feed2widget-item">
    <a href="https://www.bmj.com/careers/job/192868/gp-salaried-doctor-/?TrackID=8&amp;utm_source=rss&amp;utm_medium=feed&amp;utm_campaign=general&amp;g=w_bmj_bmj-com">Te Hau o Te Ora, Partnered Primary Care Services Limited: GP - Salaried doctor</a>  </div>
  <div class="feed2widget-item">
    <a href="https://www.bmj.com/careers/job/193166/deputy-medical-director-/?TrackID=8&amp;utm_source=rss&amp;utm_medium=feed&amp;utm_campaign=general&amp;g=w_bmj_bmj-com">Royal Cornwall Hospitals NHS Trust: Deputy Medical Director</a>  </div>
  <div class="feed2widget-item">
    <a href="https://www.bmj.com/careers/job/193063/salaried-gp/?TrackID=8&amp;utm_source=rss&amp;utm_medium=feed&amp;utm_campaign=general&amp;g=w_bmj_bmj-com">Hillview Surgery: Salaried GP</a>  </div>
  <div class="feed2widget-item">
    <a href="https://www.bmj.com/careers/job/138403/salaried-remote-gps/?TrackID=8&amp;utm_source=rss&amp;utm_medium=feed&amp;utm_campaign=general&amp;g=w_bmj_bmj-com">Babylon: Salaried Remote GPs</a>  </div>
  <div class="feed2widget-item">
    <a href="https://www.bmj.com/careers/job/192145/consultant-haematologist/?TrackID=8&amp;utm_source=rss&amp;utm_medium=feed&amp;utm_campaign=general&amp;g=w_bmj_bmj-com">Betsi Cadwaladr University Health Board: Consultant Haematologist</a>  </div>
  <div class="block-footer bmj_feed2widget">
    <a href="https://www.bmj.com/careers">View more</a>
  </div>
  </div>

  
  </div>
  </div>
</div>
</div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-snippet"  >
  
      
  
  <div class="pane-content">
    <div class="altmertrics" id="altmertrics">
  
      
  <div class="snippet-content">
    <!-- Widget start -->
<div id="altmetric"></div>
<!-- Widget end -->  </div>

</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-snippet"  >
  
      
  
  <div class="pane-content">
    <div class="oas-ad-middle-2" id="oas-ad-middle-2">
  
      
  <div class="snippet-content">
    <div id="div-gpt-ad-7326006-3"><script>
    googletag.cmd.push(function() { googletag.display('div-gpt-ad-7326006-3'); });
  </script></div>  </div>

</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-custom pane-4"  >
  
      
  
  <div class="pane-content">
    <!-- Start CrossMark Snippet v1.5 --><p><a data-target="crossmark"><img src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg" width="150" /></a></p>
<div id="crossmark-dialog" style="display: none;" title="Crossmark">
<!-- the external CrossMark data is loaded inside this iframe --><iframe id="crossmark-dialog-frame" frameborder="0"></iframe></div>
<!-- End CrossMark Snippet -->  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-snippet pane-poll-international"  id="poll-widget" >
  
        <h2 class="pane-title">
      This week&#039;s poll    </h2>
    
  
  <div class="pane-content">
    <div class="poll-international" id="poll-international">
  
      
  <div class="snippet-content">
    <p><a class="anchor" id="this-weeks-poll"></a></p>
<div id="PDI_container58250" class="PDS_Poll"></div>
<div id="PD_superContainer"></div>
<div class="poll-related">
<p><a href="https://www.bmj.com/content/376/bmj.o755">Read</a> related article</p>
<p><a href="/about-bmj/poll-archive">See</a> previous polls</p>
</div>
  </div>

</div>
  </div>

  
  </div>
        </aside>
      </div>
  </div>
  <!-- /row -->

  <div class="row">
    <div class="panel-panel page-bottom col-md-12 col-lg-12"> <div class="panel-pane pane-highwire-back-to-top"  >
  
      
  
  <div class="pane-content">
    <a href="#page" class="back-to-top"><span class="icon-chevron-up"></span> Back to top</a>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-snippet pane-oas-ad-bottom"  >
  
      
  
  <div class="pane-content">
    <div class="oas-ad-bottom" id="oas-ad-bottom">
  
      
  <div class="snippet-content">
    <div id="div-gpt-ad-7326006-4"><script>
    googletag.cmd.push(function() { googletag.display('div-gpt-ad-7326006-4'); });
</script></div>
  </div>

</div>
  </div>

  
  </div>
 </div>
  </div>
  <!-- /row -->
</div>
<!-- /container -->

</section> <!-- /.block -->
  </div>
                </section>
                            </div><!-- /row -->
        </div><!-- /main-container -->
        <!-- ______________________ FOOTER _______________________ -->
                    <div class="footer-wrapper">
                <div class="container">
                    <footer id="footer">
                          <div class="region region-footer">
    <section id="block-panels-mini-bmj-footer" class="block block-panels-mini clearfix">

      
  <div class="panel-display bootstrap-footer" id="mini-panel-bmj_footer">
  <div class="footer-top-row">
    <div id="footer-social-media" class="footer-column panel-panel col-xs-12 col-sm-3 col-md-3 col-lg-3">
      <div class="panel-pane pane-block pane-menu-block-2"  >
  
        <h2 class="pane-title">
      Follow us on    </h2>
    
  
  <div class="pane-content">
    <div class="menu-block-wrapper menu-block-2 menu-name-menu-footer parent-mlid-1298 menu-level-1">
  <ul class="menu nav"><li class="first leaf menu-mlid-1299"><a href="http://twitter.com/bmj_latest" target="_blank">Twitter</a></li>
<li class="leaf menu-mlid-1301"><a href="https://www.facebook.com/bmjdotcom" target="_blank">Facebook</a></li>
<li class="leaf menu-mlid-1300"><a href="http://youtube.com/user/BMJmedia" target="_blank">YouTube</a></li>
<li class="last leaf menu-mlid-1302"><a href="http://feeds.bmj.com/bmj/recent">RSS</a></li>
</ul></div>
  </div>

  
  </div>
    </div>
    <div class="footer-content col-xs-12 col-sm-9 col-md-9 col-lg-9">
      <div id="footer-top-row" class="row">
        <div class="footer-column panel-panel col-xs-6 col-sm-4 col-md-4 col-lg-4">
          <div class="panel-pane pane-block pane-menu-block-3"  >
  
        <h2 class="pane-title">
      Content links    </h2>
    
  
  <div class="pane-content">
    <div class="menu-block-wrapper menu-block-3 menu-name-menu-footer parent-mlid-1303 menu-level-1">
  <ul class="menu nav"><li class="first leaf menu-mlid-125058"><a href="http://www.bmj.com/collections">Collections</a></li>
<li class="leaf menu-mlid-125036"><a href="http://www.bmj.com/health-in-south-asia">Health in South Asia</a></li>
<li class="leaf menu-mlid-125034"><a href="http://www.bmj.com/content/women%E2%80%99s-children%E2%80%99s-and-adolescents%E2%80%99-health-0">Women’s, children’s &amp; adolescents’ health</a></li>
<li class="leaf menu-mlid-17959"><a href="http://www.bmj.com/freezikaresources">Zika virus</a></li>
<li class="leaf menu-mlid-1305"><a href="/us/research">Research</a></li>
<li class="leaf menu-mlid-1306"><a href="/us/education">Education</a></li>
<li class="leaf menu-mlid-6506"><a href="/us/news">News and views</a></li>
<li class="leaf menu-mlid-1310"><a href="http://blogs.bmj.com/bmj/">BMJ Opinion</a></li>
<li class="leaf menu-mlid-7612"><a href="/rapid-responses">Rapid responses</a></li>
<li class="last leaf menu-mlid-1309"><a href="/archive">Archive</a></li>
</ul></div>
  </div>

  
  </div>
        </div>
        <div class="footer-column panel-panel col-xs-6 col-sm-4 col-md-4 col-lg-4">
          <div class="panel-pane pane-block pane-menu-block-4"  >
  
        <h2 class="pane-title">
      About us    </h2>
    
  
  <div class="pane-content">
    <div class="menu-block-wrapper menu-block-4 menu-name-menu-footer parent-mlid-1314 menu-level-1">
  <ul class="menu nav"><li class="first leaf menu-mlid-6487"><a href="/about-bmj">About us</a></li>
<li class="leaf menu-mlid-1316"><a href="/about-bmj/editorial-staff">Editorial staff</a></li>
<li class="leaf menu-mlid-1317"><a href="/about-bmj/editorial-staff/bmj-united-states">BMJ in the USA</a></li>
<li class="leaf menu-mlid-1318"><a href="/about-bmj/editorial-staff/bmj-south-asia">BMJ in South Asia</a></li>
<li class="leaf menu-mlid-1319"><a href="/about-bmj/advisory-panels">Advisers</a></li>
<li class="leaf menu-mlid-1320"><a href="/about-bmj/resources-authors/forms-policies-and-checklists">Policies</a></li>
<li class="last leaf menu-mlid-1323"><a href="http://mc.manuscriptcentral.com/bmj">Submit your paper</a></li>
</ul></div>
  </div>

  
  </div>
        </div>
        <div class="footer-column panel-panel col-xs-6 col-sm-4 col-md-4 col-lg-4">
          <div class="panel-pane pane-block pane-menu-block-5"  >
  
        <h2 class="pane-title">
      Resources    </h2>
    
  
  <div class="pane-content">
    <div class="menu-block-wrapper menu-block-5 menu-name-menu-footer parent-mlid-1324 menu-level-1">
  <ul class="menu nav"><li class="first leaf menu-mlid-1325"><a href="/about-bmj/resources-authors">Authors</a></li>
<li class="leaf menu-mlid-1326"><a href="/about-bmj/resources-reviewers">Reviewers</a></li>
<li class="leaf menu-mlid-1327"><a href="/about-bmj/resources-bma-members">BMA members</a></li>
<li class="leaf menu-mlid-1329"><a href="/about-bmj/resources-readers">Readers</a></li>
<li class="leaf menu-mlid-1328"><a href="/about-bmj/resources-subscribers">Subscribers</a></li>
<li class="leaf menu-mlid-1330"><a href="/about-bmj/resources-advertisers-and-sponsors">Advertisers and sponsors</a></li>
<li class="leaf menu-mlid-1331"><a href="/about-bmj/resources-media">Media</a></li>
<li class="last leaf menu-mlid-7610"><a href="https://recruiter.bmj.com/">Recruiters</a></li>
</ul></div>
  </div>

  
  </div>
        </div>
        <div class="footer-column panel-panel col-xs-6 col-sm-4 col-md-4 col-lg-4">
          <div class="panel-pane pane-block pane-menu-block-6"  >
  
        <h2 class="pane-title">
      Explore BMJ    </h2>
    
  
  <div class="pane-content">
    <div class="menu-block-wrapper menu-block-6 menu-name-menu-footer parent-mlid-1332 menu-level-1">
  <ul class="menu nav"><li class="first leaf menu-mlid-7613"><a href="https://www.bmj.com/company/?int_source=tbmj&amp;int_medium=footer&amp;int_campaign=URLswitch">Our company</a></li>
<li class="leaf menu-mlid-7421"><a href="https://jobs.bmj.com/">BMJ Careers</a></li>
<li class="leaf menu-mlid-7423"><a href="http://learning.bmj.com/">BMJ Learning</a></li>
<li class="leaf menu-mlid-7424"><a href="http://masterclasses.bmj.com">BMJ Masterclasses</a></li>
<li class="leaf menu-mlid-7425"><a href="http://journals.bmj.com">BMJ Journals</a></li>
<li class="leaf menu-mlid-7422"><a href="/student">BMJ Student</a></li>
<li class="leaf menu-mlid-7426"><a href="http://www.bmj.com/about-bmj/resources-readers">Academic edition of The BMJ</a></li>
<li class="leaf menu-mlid-7427"><a href="http://bestpractice.bmj.com/">BMJ Best Practice</a></li>
<li class="last leaf menu-mlid-17958"><a href="http://thebmjawards.bmj.com/home">The BMJ Awards</a></li>
</ul></div>
  </div>

  
  </div>
        </div>
        <div class="footer-column panel-panel col-xs-6 col-sm-4 col-md-4 col-lg-4">
          <div class="panel-pane pane-block pane-menu-block-7"  >
  
        <h2 class="pane-title">
      My account    </h2>
    
  
  <div class="pane-content">
    <div class="menu-block-wrapper menu-block-7 menu-name-menu-footer parent-mlid-1343 menu-level-1">
  <ul class="menu nav"><li class="first leaf menu-mlid-1344"><a href="http://myaccount.bmj.com/myaccount/account/hw-registration.html">Email alerts</a></li>
<li class="last leaf menu-mlid-1345"><a href="http://journals.bmj.com/cgi/activate">Activate subscription</a></li>
</ul></div>
  </div>

  
  </div>
        </div>
        <div class="footer-column panel-panel col-xs-6 col-sm-4 col-md-4 col-lg-4">
          <div class="panel-pane pane-block pane-menu-block-8"  >
  
        <h2 class="pane-title">
      Information    </h2>
    
  
  <div class="pane-content">
    <div class="menu-block-wrapper menu-block-8 menu-name-menu-footer parent-mlid-1346 menu-level-1">
  <ul class="menu nav"><li class="first leaf menu-mlid-1347"><a href="/about-bmj/contact-us">Contact us</a></li>
<li class="last leaf menu-mlid-1321"><a href="/about-bmj/complaints-procedure">Complaints</a></li>
</ul></div>
  </div>

  
  </div>
        </div>
      </div>
    </div>
  </div>

  <div id="footer-bottom-row" class="row">
    <div class="panel-panel col-xs-12 col-sm-12 col-md-12 col-lg-12">
      <div class="panel-pane pane-block pane-menu-block-9 hidden-phone"  >
  
      
  
  <div class="pane-content">
    <div class="menu-block-wrapper menu-block-9 menu-name-menu-footer parent-mlid-1349 menu-level-1">
  <ul class="menu nav"><li class="first leaf menu-mlid-125888"><a id="ot-sdk-btn" class="ot-sdk-show-settings" clickable="false">Cookie settings</a></li>
<li class="leaf menu-mlid-1350"><a href="https://www.bmj.com/company/your-privacy/cookies-policy/">Cookie Policy</a></li>
<li class="leaf menu-mlid-125299"><a href="https://www.bmj.com/company/your-privacy/">Privacy policy</a></li>
<li class="leaf menu-mlid-1351"><a href="http://www.bmj.com/company/legal-information/">Website T&amp;Cs</a></li>
<li class="leaf menu-mlid-1352"><a href="http://group.bmj.com/group/about/revenue-sources">Revenue Sources</a></li>
<li class="leaf menu-mlid-1353"><a href="http://home.highwire.org/">HighWire Press</a></li>
<li class="last leaf menu-mlid-8093"><a href="/sitemap">Sitemap</a></li>
</ul></div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-bmj-copy-right"  >
  
      
  
  <div class="pane-content">
    
<div class="copyright">Copyright © 2023 BMJ Publishing Group Ltd</div>
  </div>

  
  </div>
    </div>
  </div>

</div>

</section> <!-- /.block -->
  </div>
                    </footer> <!-- /footer -->
                </div><!-- /footer-wrapper:container -->
            </div><!-- /footer-wrapper -->
        
        
    </div> <!-- /wrapper -->
</div> <!-- /wrapper-outer -->
  <script src="https://www.bmj.com/sites/default/files/advagg_js/js__uW7NyUocxI-7E_sL-GP7L5FYvHrfi0D8UkwaFa_jFUQ__ITpTmydBN18ujP4Nq9igNKs2_uPvSa_MMIGZilNH7xo__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.js"></script>
<script src="https://www.bmj.com/sites/default/files/advagg_js/js__ADNpAJRqEZQTdJr17qFcuXkfatW9ULGGExiAh_zWtxs__Xan4DQzBMVgws81Yi1i-_1Amp0wkg5IKAA2fCWPVSwI__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.js"></script>
<script src="https://www.bmj.com/sites/default/files/advagg_js/js__L2RNsEq1_BwrvVr4-XqL6HCM3TrId8FewyOD-ifl56Y__xFUWwD-CmrvIMpj7PKKOzG6M0u5x4a4YsfZcc7fa3qg__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.js"></script>
<script src="https://www.bmj.com/sites/default/files/advagg_js/js__wteGLiD1wamodYGt1CPf350dgG_dnSPaybjTJJ4V8O0__tHSi0oVxXVY1K8dKSadgniknKfq0JO39EkwFnl-Qx3k__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.js"></script>
<script src="https://static.polldaddy.com/w/58250.js"></script>
<script src="https://ajax.googleapis.com/ajax/libs/jqueryui/1.8.7/jquery-ui.min.js"></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script>
<script src="https://www.bmj.com/sites/default/files/advagg_js/js__SFoHIUTheqo0e4hxRINC0gFp_rO4LFMUUrC70xvOwtY__h5zRuwNt-m_fFPTyMKF2APwK7ArnJ2U3S4dW5Cp_p_o__a7Jq5VSqcMKMeR_gboGw1x4AC4g6SRpO1Geb_4xJjYc.js"></script>
<script>
setTimeout(function(){var a=document.createElement("script");
var b=document.getElementsByTagName("script")[0];
a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0014/4896.js?"+Math.floor(new Date().getTime()/3600000);
a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script>
<script>jQuery(".page-search .pane-quick-search-results .search-snippet").text(function (_, old){ return old.replace(/\S+@\S+\.\S+/, "");});</script>
  <script type="text/javascript">
/* <![CDATA[ */
var google_conversion_id = 973817434;
var google_custom_params = window.google_tag_params;
var google_remarketing_only = true;
/* ]]> */
</script>
<script type="text/javascript" src="//www.googleadservices.com/pagead/conversion.js">
</script>
<noscript>
<div style="display:inline;">
<img height="1" width="1" style="border-style:none;" alt="" src="//googleads.g.doubleclick.net/pagead/viewthroughconversion/973817434/?value=0&amp;guid=ON&amp;script=0"/>
</div>
</noscript>
  
  <script async src="https://cdn.pbgrd.com/core-bmj.js"></script>
</body>
</html>
